Subject Index

Notes:
Entries for the major viruses and the resultant infections have been kept separate for convenience. In such cases, antibodies, diagnostic techniques and vaccines have been listed under the entry relating to the infection, not the virus.

Page numbers in italics refer to figures and tables.
This index is in letter-by-letter order, whereby spaces and hyphens between words are excluded from alphabetization (e.g. B lymphocytes comes after blue river virus, and not at the start of the ‘B’ section)

Abbreviations:
3TC see lamivudine (3TC)
CCHF - Crimean-Congo haemorrhagic fever
CMV - cytomegalovirus
EEEV - Eastern equine encephalitis virus
HAM/TSP - HTLV-associated myelopathy/tropical spastic paraparesis
HBV - hepatitis B virus
HCV - hepatitis C virus
HCWs - health-care workers
HHV - human herpesvirus (e.g. HHV-6)
HIV - human immunodeficiency virus
HPV - human papillomavirus
HSCT - haematopoietic stem cell transplant
HSV - herpes simplex virus
KSHV - Kaposi’s sarcoma-associated herpesvirus (HHV-8)
MCD - multicentric Castleman’s disease
PCR - polymerase chain reaction
PIV - parainfluenza virus
PML - progressive multifocal leukoencephalopathy
PTLD - post-transplant lymphoproliferative disease
SSPE - subacute sclerosing panencephalitis
TK - thymidine kinase
VEEV - Venezuelan equine encephalitis virus
WEEV - Western equine encephalitis virus
14–13–13 protein 949–950
A
A-315675 397
abacavir (ABC) in HIV infection 923
resistance 923
Abbott Determine test 907
abdominal pain, serological testing not indicated 21
abortion, spontaneous
Lassa fever 749
mumps 597
parvovirus B19V infection 862
Rift Valley fever virus 716
rubella 570
ACE2, coronavirus receptor 517, 518
aciclovir
CMV infection 186
prophylaxis 186, 187–188
EBV infection 210
infectious mononucleosis 210, 211
PTLD 217
HSV infections 108–109, 113, 114, 116
encephalitis 122
meningitis 124
neonatal 125
mechanism of action 108–109, 111
oral, absorption problem 151
in pregnancy 152
resistance, HSV 111–112
structure 109
VZV infections 148
herpes zoster 152, 153
inhibitory concentration (ID50) 151
ophthalmic zoster 153
prophylactic 154
varicella 151, 152
acidophilic bodies 273
acquired immune deficiency syndrome (AIDS) see AIDS
actin, PIV3 RNA synthesis 414
acute otitis media see otitis media
acute respiratory disease (ARD) adenoviruses 463, 473–474
HPV causing 420, 423–424
TTV and 329
see also respiratory tract infections
acyclovir see aciclovir
adaptive immune system 83–84
ADAR (adenosine deaminase, RNA-specific), in SSPE 549
adefovir dipivoxil
hepatitis B 301–302
resistance, HBV 302
adenine deaminase deficiency, gene therapy 872
adenoid-degeneration agent 464
Adenoviridae 357, 463, 464
Adenovirus, physical characteristics 50
adenoviruses 463–488
assembly 467, 468
attachment and infection process 467
capsid 466
cell culture 478
classification 463
cytopathic effect 478
delayed early genes 466, 468
DNA polymerase 465
DNA replication 467–468
E1-A, E1-B proteins 467, 470
E3 and E4 products 467–468
electron microscopy 467, 468, 478
enteric see enteric adenoviruses
fibres 466
genome (dsDNA) 465–466
genotype 7b 473
genotype 7a 471
gp19 469
hexons 466
history/discovery 464
host mRNA shutdown 469
immediate-early genes 466, 467
immune evasion 467, 469, 470
interferon-induced gene expression blocked 467
isolation 478
late genes 466, 468
latent (persistent) infection 468, 469

Subject Index

Adenovirus infections 245

Aedes aegypti 74

Aedes albopictus 74
dengue 680, 681
yellow fever 674, 676, 677

AIDS

AIDS dementia complex (ADC) 914

Aichi virus 364

Alphavirus 643

Allergic response

rhinoviruses and allergen exposure 496

see also hypersensitivity reactions

Alloherpesviridae

Alpharetroviruses 872

Alphatoxusvirunus 326, 327

Alphavirus 643

alpahvirus 643–668

antigenic classification 644

antigenic properties 646–647

biochemical/biophysical properties 644–645

cDNA clones 646

cell culture 647

distribution, hosts and vectors 644

genoate (positive-sense ssRNA) 643–644,

644–645

organization 646

genotypes 646–647

glycoproteins (E1 and E2) 643, 645–646

AIDS

AIDS dementia complex (ADC) 914

Aichi virus 364

Alphavirus 643

allergic response

rhinoviruses and allergen exposure 496

see also hypersensitivity reactions

Alloherpesviridae

Alpharetroviruses 872

Alphatoxusvirunus 326, 327

Alphavirus 643

alpahvirus 643–668

antigenic classification 644

antigenic properties 646–647

biochemical/biophysical properties 644–645

cDNA clones 646

cell culture 647

distribution, hosts and vectors 644

genoate (positive-sense ssRNA) 643–644,

644–645

organization 646

genotypes 646–647

glycoproteins (E1 and E2) 643, 645–646

AIDS

AIDS dementia complex (ADC) 914

Aichi virus 364

Alphavirus 643

allergic response

rhinoviruses and allergen exposure 496

see also hypersensitivity reactions

Alloherpesviridae

Alpharetroviruses 872

Alphatoxusvirunus 326, 327

Alphavirus 643

alpahvirus 643–668

antigenic classification 644

antigenic properties 646–647

biochemical/biophysical properties 644–645

cDNA clones 646

cell culture 647

distribution, hosts and vectors 644

genoate (positive-sense ssRNA) 643–644,

644–645

organization 646

genotypes 646–647

glycoproteins (E1 and E2) 643, 645–646

AIDS

AIDS dementia complex (ADC) 914

Aichi virus 364

Alphavirus 643

allergic response

rhinoviruses and allergen exposure 496

see also hypersensitivity reactions

Alloherpesviridae

Alpharetroviruses 872

Alphatoxusvirunus 326, 327

Alphavirus 643

alpahvirus 643–668

antigenic classification 644

antigenic properties 646–647

biochemical/biophysical properties 644–645

cDNA clones 646

cell culture 647

distribution, hosts and vectors 644

genoate (positive-sense ssRNA) 643–644,

644–645

organization 646

genotypes 646–647

glycoproteins (E1 and E2) 643, 645–646

AIDS

AIDS dementia complex (ADC) 914

Aichi virus 364

Alphavirus 643

allergic response

rhinoviruses and allergen exposure 496

see also hypersensitivity reactions

Alloherpesviridae

Alpharetroviruses 872

Alphatoxusvirunus 326, 327

Alphavirus 643

alpahvirus 643–668

antigenic classification 644

antigenic properties 646–647

biochemical/biophysical properties 644–645

cDNA clones 646

cell culture 647

distribution, hosts and vectors 644

genoate (positive-sense ssRNA) 643–644,

644–645

organization 646

genotypes 646–647

glycoproteins (E1 and E2) 643, 645–646

AIDS

AIDS dementia complex (ADC) 914

Aichi virus 364

Alphavirus 643

allergic response

rhinoviruses and allergen exposure 496

see also hypersensitivity reactions

Alloherpesviridae

Alpharetroviruses 872

Alphatoxusvirunus 326, 327

Alphavirus 643

alpahvirus 643–668

antigenic classification 644

antigenic properties 646–647

biochemical/biophysical properties 644–645

cDNA clones 646

cell culture 647

distribution, hosts and vectors 644

genoate (positive-sense ssRNA) 643–644,

644–645

organization 646

genotypes 646–647

glycoproteins (E1 and E2) 643, 645–646

AIDS

AIDS dementia complex (ADC) 914

Aichi virus 364

Alphavirus 643

allergic response

rhinoviruses and allergen exposure 496

see also hypersensitivity reactions

Alloherpesviridae

Alpharetroviruses 872

Alphatoxusvirunus 326, 327

Alphavirus 643

alpahvirus 643–668

antigenic classification 644

antigenic properties 646–647

biochemical/biophysical properties 644–645

cDNA clones 646

cell culture 647

distribution, hosts and vectors 644

genoate (positive-sense ssRNA) 643–644,
Subject Index

971

haemagglutination inhibition (HI) 646
hosts 643
IgM assays 647
infections
case definition 648
diagnosis and isolation 647
encephalitis associated 656–661
fevers and polyarthritis 648–656
management and prevention 647–648
spectrum of diseases 647
lipid bilayer 643
of medical importance 647
nonstructural proteins 644, 645
replication 645–646
RT-PCR 652
rubella virus similarity 562
structure/morphology 643–644, 645
rubella virus RNA 580
influenza virus 392
infections
IgM assays 647
avidity tests, HHV-6 and HHV-7 237
detection 5–7
in body fluids 6
formation and types 83
heterophile, EBV infection 207, 209
neutralizing 4, 5, 84
protective 85
protective mechanisms 84
response
primary/secondary 84
time-course 5
see also individual immunoglobulins: individual infections
antibodies
avidity tests, HHV-6 and HHV-7 237
detection 5–7
in body fluids 6
formation and types 83
heterophile, EBV infection 207, 209
neutralizing 4, 5, 84
protective 85
protective mechanisms 84
response
primary/secondary 84
time-course 5
see also individual immunoglobulins: individual infections
antibody-dependent cellular cytotoxicity (ADCC) 84
antigen(s) 84
detection 2–3, 3–5
samples 4
dose, in vaccines 86
protective, in pathogens 85–86
T-dependent 84
T-independent 84
viral see individual viruses
antigenic drift, influenza virus 70, 383, 383–384, 394, 401
antigenic shift
definition 382
influenza virus 381–383, 382, 402
antigenome replication, measles virus 539
antigen presenting cells (APCs) 83, 84
measles virus infection 542
see also dendritic cells (DCs)
anti-HBV antibodies see hepatitis B virus (HBV)
anti-HBe antibodies see hepatitis B virus (HBV)
anti-HBs antibodies, HBV 288, 290, 290
anti-herpetic drugs 108–112, 913
antihistamines, common colds 494, 500
antiretroviral drugs, in HIV infection classes and individual drugs 921, 921–929
developing countries 918, 930
‘early start’ principle 917
early triple therapy 917, 921, 925
effects on morbidity/mortality 916
entry inhibitors 921, 928–929
amantadine
hepatitis C 316
influenza 60, 396–398
hepatitis C 316
Amur virus 734
Amapari virus 734
Anellovirus 791, 792
Anoegenital squamous carcinoma, HIV 871
Apelin, coronavirus infection treatment 526
Anaplasmaphagocytophilum, T cells 338
Anaplasma phagocytophilum, T cells 338
anemia
anemias 382
Anopheles 704
American bat rabies viruses 791, 792
aminopeptidase N (APN), coronavirus receptor 517
amniotic fluid
CMV detection 176, 178, 182
rubella virus RNA 580
amplification techniques see molecular amplification techniques; polymerase chain reaction (PCR)
AmpliGen, coronavirus infection treatment 526
Anaplasma phagocytophilum, T cells 338
amyl nitrate (‘poppers’), KSHV risk factor 250
anasia
Chronic B19V infection 861, 862, 863
Diamond-Blackfan anemia 721, 722
Anellovirus 791, 792
Anoegenital squamous carcinoma, HIV 871
Antibodies
antibodies
aviansensitivity, in pathogens 85–86
T-dependent 84
T-independent 84
viral see individual viruses
antigenic drift, influenza virus 70, 383, 383–384, 394, 401
antigenic shift
definition 382
influenza virus 381–383, 382, 402
antigenome replication, measles virus 539
antigen presenting cells (APCs) 83, 84
measles virus infection 542
see also dendritic cells (DCs)
anti-HBV antibodies see hepatitis B virus (HBV)
anti-HBe antibodies see hepatitis B virus (HBV)
anti-HBs antibodies, HBV 288, 290, 290
anti-herpetic drugs 108–112, 913
antihistamines, common colds 494, 500
antiretroviral drugs, in HIV infection classes and individual drugs 921, 921–929
developing countries 918, 930
‘early start’ principle 917
early triple therapy 917, 921, 925
effects on morbidity/mortality 916
entry inhibitors 921, 928–929
HAART see HAART
integrase inhibitors 921, 929
monitoring 17, 917–921
NNRTIs 921, 924–925, 925
protease inhibitors 903, 921, 925–928
resistance 19, 20, 918–920
cross-resistance 921–922
genotypic assays 19, 19–20, 918, 919
genotyping 918
lamivudine, M184V 920, 921, 923
mechanisms of development 918–919
NNRTIs 921, 923–924, 925, 923, 925, 929
NRTIs 921, 923–924, 924
phenotypic assays 19, 19, 918–919, 919, 920
principles 918
protease inhibitors 926, 926
TDF, K65R 920, 923
testing 918
tropism assays 920
use testing in clinical practice 919, 919
viral fitness cost 920–921
sites of action 922
targets 901–903
triple therapy, prophylactic 931
vertical transmission prevention 929–930
see also individual classes for further entries
antisense inhibitors
hepatitis C treatment 316
rubella virus infections 501
antiviral drugs/therapy
antiretrovirals see antiretroviral drugs, in HIV infection
monitoring by molecular techniques 17–18
see also individual drug groups; individual virus infections
antiviral resistance detection 18–20
antiretrovirals see antiretroviral drugs, in HIV infection
genotypic assays 19, 19–20, 918, 919
phenotypic assays 19, 19, 918–919, 919, 920
AP-1 transcription factors 810
Apes, great
filovirus infections 755–756, 762
see also primates
Apeu virus 702, 710
aphthoviruses 601
aplastic crises, parvovirus B19 infections 57
apnoea, RSV infection 448, 452
Apodemus field mice 721, 722
apoptosis 84
inhibition
adenovirus infections 470
JC virus 825, 841
KSHV infections 256, 259–260
neuronal, rabies 784
pathways 256, 259
PrP$\alpha$ role 945
regulator (survivin) 259, 825, 840
rubella-induced caspase-dependent 565, 569
of T cells see T lymphocytes, apoptosis
apoptosis-linked gene 2 interacting protein (Alx) 903
Araqua virus 704
arachidonic acid pathway, rhinovirus infections 494
Aravan virus 779
arenaviruses 733–754
Arenaviridae 733
arboviruses 669
Aravan virus 779
arachidonic acid pathway, rhinovirus 704
Araquara virus
new/emerging 74–75
clades A-C
chemical composition 737–739
cell culture 737, 739, 740
antigenic site 737
antigenic relationships 741
ambisense coding strategy 738, 740
flaviviruses
bunyaviruses 699, 701
alphaviruses
see New World 733–734, 734
natural reservoir (hosts) 733, 734, 735
natural history 733–735
monoclonal antibodies to 741
L RNA 737, 738
L protein 738
nomenclature/classification 733–735
N (nucleocapsid) protein 737, 738, 740
nucleotide sequencing 734
Old World 733, 734, 735, 737, 738–739
 persistence 742, 743–744
phylogenetic analysis 738–739
proteins 737–738
receptor 742
replication 737, 739–740, 742
ribosomal RNA 738
RNA polymerase 738, 740
RNA transcription into cDNA 744
S RNA 737, 738, 740
structure 735–737, 736
Tacaribe serocomplex 734, 734
transmission 733
Z protein 738
see also Junín virus; Lassa virus; lymphocytic choriomeningitis virus (LCMV);
Machupo virus; other specific viruses (see page 734)
Argentine haemorrhagic fever (AHF) 733, 746–747
antibodies 745–746
clinical/pathological features 746, 746
diagnosis 745–746
epidemiology 746, 746
pathogenesis 744
prophylaxis (vaccine) 747, 750
treatment (immune plasma) 746–747
see also Junín virus
arthralgia
Barmah Forest virus (BFV) 655
Chikungunya virus infection 649, 651
dengue fever 681
mumps 597
o’nyong-nyong virus infection 652
Ross River virus infection 653
serological testing 22
Sindbis virus infection 649
Zika fever 684
see also joint involvement
arthritis, chronic, B19V role 861
arthropathy, human parvovirus B19 (B19V) 860–861
arthropod-borne viruses see arboviruses
artificially-induced immunity 83
ascorbic acid, rhinovirus infection treatment 500–501
aspartate aminotransferase (AST) 275
Ebola haemorrhagic fever 765
Lassa fever 749
aspirin, Reye’s syndrome 390
asthma
exacerbation
coronavirus infections 521
rhinovirus infection 495, 497–498
RSV infection sequelae 449–450
astrocytes
BK virus infection 840
progressive multifocal leukoencephalopathy (PML) 841, 842, 843, 845
Astroviridae 363
Astrovirus, physical characteristics 50
astroviruses 363–364
classification 363
genome 360, 363
infections
clinical aspects 363
diarrhoea 355
epidemiology 363–364
pathogenesis 363
 persistence in environment 49
replication and cell culture 363
serotypes 1–4 364
structure 356, 363
transfection of RNA 363
transmission 364
Aviadenovirus 464
atazanavir, HIV infection 927
atox
coronavirus infections 521
rhinovirus infections 496
RSV infection and 450
attenuation, of viruses 86
atypical squamous cells of unknown significance (ASCUS) 818
aural zoster 146
Aurora virus (AURAV) 644, 644, 658
Australia antigen see hepatitis B virus (HBV), HBsAg
Australian bat lyssavirus (ABL) 778, 779
human infections 793–794
autism, MMV vaccine and 90, 581
autoantibodies
congenital rubella syndrome 575
EBV infection 207
hepatitis B 290
thyroid 575
autocrine loop theory 887
autoimmunity
enteroviruses and diabetes link 614
see also autoantibodies
automation
molecular amplification techniques 15, 23, 106–107
nucleic acid sequencing 20
testing methods 23
Aviadenovirus 464
avian influenza virus 74, 376, 386
antigenic shift 382
HN1 383
receptors 378
transmission to humans 381, 383
clinical features 388
see also influenza A virus, H5N1
avian metapneumovirus 73
Avulavirus 410
axonal movement, retrograde, rabies virus 784
AxSYM HIV assay 908
B
B19V see human parvovirus B19 (B19V)
Babani virus 648
Babes' nodules 797
babooinogenous virus (BaEV) 872
baclofen, HAM treatment 890
bacterial infections, secondary
herpes zoster 147
smallpox 629
varicella 144
baculovirus
influenza vaccine development 402–403
parvovirus B19V vaccine development 865
Bangui virus 705, 726
Banzi virus 673
Barmah Forest virus (BFV) 644, 646, 654–655
Subject Index

973

clinical disease and diagnosis 655
epidemiology and host range 654–655
genome 654
basic reproductive rate/number (Ro) 82, 89
CMV infection 184
SARS-CoV 519–520
Batai virus 702, 706
bats
Ebola virus reservoir 762, 769
Marburg virus reservoir 761–762, 769
rabies 782, 783, 787, 801
SARS-like coronavirus 519
as virus vectors 75–76, 76–77
see also fruit bats
Bayou virus 704, 725
B-cell lymphoma
EBV and 216
in HIV infection 915–916
polyomaviruses (JCV) 843
B cells see B lymphocytes
BGG, rubella vaccine with 582
Bcl-2, KSHV homologue 259
bDNA assay 14, 311
Bcl-2, KSHV homologue 259
BDProbeTec 14
Bear Canyon virus
blood/blood-product transfusions
blood, maternal, virus transmission via 32
bladder cancer, BK virus 843
'black vomit' 676
BCLN-2061, hepatitis C treatment 316
bilirubin 275
β
Bayou virus 704
bats
Batai virus
basic reproductive rate/number (Ro) 82, 89
heterologous transactivation of transcription 831
infection/diseases 838–840, 839
antibodies 833, 845–846
CNS disease 836, 839–840
course of 834
diagnostic evaluation 843, 844–845
IgA 845–846
IgM 833, 845
immune response 845–847
pathology 839, 840
persistent 834–836, 838, 843
prediction 16
pregnancy 845
primary infections 833, 838
treatment 847–848
tumours associated 843
isolation 833
JCV co-infection 836
large TAg 825, 842, 843
cycle 824–825
lymphoid cell interactions 835
noncoding control region 830
oncogenicity 841–843
PCR 844–845
proteins 828
receptors 824–825
shedding/viruria 837, 838, 848
small TAg 826, 842
in tonsils 835
transcriptional control region (TCR) 830, 833
transcriptional expression and control 830
transcription factor action 830
transmission 833
urotheliotropic virus 834, 838
viremia and virus load 837, 838
VP1 833
Black Creek Canal virus 704, 725
‘black vomit’ 676
bladder cancer, BK virus 843
blood, maternal, virus transmission via 32
blood/blood-product transfusions
CJD transmission 954
CMV transmission 168
prevention 184
donor screening 30–31
HBV and HBsAg mutants 295–296
HCV 311
HTLVs 891
policies and testing methods 30–31
GV-C transmission 324
HBV transmission 295–296
HCV transmission 31, 309, 311, 313
HTLV-1 transmission 884, 891
KSHV transmission 247–248, 251
parvovirus B19V transmission 859
patient-to-patient transmission 30–31
risk of virus transmission and 31, 31
TTV transmission 330
viral inactivation methods 31
virus transmission 29
blood-borne viruses (BBVs) 29–40, 31, 3I
HBV 33, 35, 35
HCV 33, 35
HCV-to-patient transmission 36–38
HIV 33, 35, 36–38
patient-to-HCW transmission 32–36, 36
epidemiology 32–33
post-exposure prevention 34, 34–36
pre-exposure prevention 34
surveillance 32–33
patient-to-patient transmission 30–32
prevention of exposure 34–36
infection control 30
transmission settings 29
risk assessment 30
see also blood/blood-product transfusions
blood-contaminated instruments/environments, virus transmission 32
Bloodland Lake virus 704
Blue River virus 704
B lymphocytes 83
activation 212
by EBV 202, 204
polyclonal 216
BK virus infection 835
Burkitt’s lymphoma 212
EBV infection 200, 204, 206, 210
JC virus infection 836
memory, EBV infections 205
proliferation, KSHV infection 258–259
receptor, inhibition by EBV 203
transformation by EBV 201–202, 204
vIL-6 expression, KSHV infection 253, 253
B lymphoproliferative disease (BLPD), EBV and 206
Bocavirus 74, 854
bocaviruses 853, 854
body fluids
CMV in 178–179, 179
precautions on handling 29
see also specific fluids
Bolivian haemorrhagic fever 747–748
antibodies 745–746
clinical features 747
diagnosis 745–746
epidemiology 747
treatment (immune plasma/rhabiravirin) 747–748
see also Machupo virus
bone marrow, TTV infections 330
bone marrow transplant recipient
adenovirus infections 475–476, 476
BK virus infection 835, 837
CMV infection 168
prevention/ prophylaxis 183, 186
treatment 186
HHV-6 infection 235–236
HPV infections 424
see also haematopoietic stem cell transplant (HSCT) recipients
Bornholm disease 612
bovine coronavirus (BCoV), receptors 518
congenital malformations (contd.)

rubella see congenital rubella syndrome (CRS)

rubella virus transmission 786, 788

Coronaviridae 365, 511

Coronavirus, physical characteristics 50

coronaviruses 511–531

antigenic structure 517

assembly of virions 516

attachment and infection process 517–519

cell attachment proteins 517

classification 511, 512

deletion mutants 518

electron microscopy 511–512, 514, 524

enteric 514

epithelium mapping 517

E protein 513, 516

experimental models 521

fusion process 519

genes 515

gene expression (positive sense ssRNA) 511

genome organization 515–516, 526

glycans on receptors 518

groups 511, 512, 513

HCoV-Oc43; HCoV-229E see entries beginning human coronavirus

HE glycoprotein 514, 517, 518

host range 517, 518–519

incubation period 520

interspecies transmission (animals) 518

isolation 524

M protein (type II glycoprotein) 512–513, 516

new/emerging 74

see also SARS-CoV

N protein 513–514

permissiveness in environment 49

phylogeny 513, 517

proteins 512–514, 516

receptors for 517–518

RT-PCR 523, 524

SARS see SARS-CoV

S protein (type I glycoprotein) 512, 517, 518, 519

structure 511–512, 514, 515

transcription and replication 514–516, 516

transcription regulatory sequence (TRS) 515

virion release 512

see also individual coronaviruses

coronavirus (CoV) infections

acute diarrheal disease 365, 522

antibodies 517, 519, 525

cross-neutralizing paratypes 525

monoclonal 525

asthma exacerbation 521

clinical features 520–523

CNS, multiple sclerosis and 522

common colds 511, 520

diagnosis 523–525

RT-PCR 523, 524

serology 524

specimens 523

virus isolation/detection 524

enteric 512

epidemiology 519–520

immunization active 525

passive 525–526

nosocomial 521

pathogenesis 517–519, 523

pathology 523

prophylaxis 525–526

reinfections 519

SARS see SARS

treatment 526

vaccines 525

corticosteroids

rhinovirus infections 500, 501

RSV infection 453

see also steroid therapy

cot death syndrome, influenza 391

cotton rat

denovirus infections 469

measles virus infection 539, 545

cottontail rabbit papillomavirus (CRPV) 813

cough

denovirus 388, 396

RSV infection 447

Councilman bodies 677

Councilman-like bodies

arenavirus infections 744

Ebola and Marburg haemorrhagic fevers 768–769

Cowdry bodies 176–177, 544, 551

cowpox 81, 631–632

clinical features 631–632

IgM detection 633

cowpox virus

Brighton strain 626

host, distribution 626

cowpox–adenovirus receptor (CAR) protein 605

denovirus receptor 466

cossackievirus group A (CVA) 607

Bornholm disease 612

characteristics 608

CVA1, diarrhoea associated 364

CVA9, rubelliform rashes 613

CVA21 (CoV virus) 613

CVA24 613

hand, foot and mouth disease 612–613

herpangina 612

host range 609

isolation/detection 615, 616

meningitis 610

 persistence in environment 49

respiratory infections 613

rubelliform rashes 613

cossackievirus group B (CVB) 607

acute pancreatitis 614

Bornholm disease 612

characteristics 608

chronic fatigue syndrome and 614

conjunctivitis 613

CVB2 613

CVB3 605, 617

hand, foot and mouth disease 612–613

host range 609

isolation/detection 615, 616

meningitis 610

molecular diagnosis 616

murine disease 612

myocarditis 610–611
cytomegalovirus (CMV) infection (contd.)

HIV interaction mechanisms 172–173

treatment 189, 190, 191

antibodies

age-specific prevalence 166, 167

detection 6, 179–180

IgG 166, 167, 171, 179, 179–180

IgG as marker of acute infection 179–180

IgG as marker of past infection 179

IgM 6, 171, 180, 182

basic reproductive number 184

childhood 166

clinical features 173–175

CNS involvement 173

congenital 47, 167

asymptomatic 173–174, 180

clinical features 173–174

diagnosis 176, 177

management 180–181

prevention 183

prognosis 180, 183

symptomatic 173, 175, 180, 183

testing for/investigations 180

transmission 167

cytotoxic T cells 171

diagnosis 175–180

advantages/disadvantages of virus detection 178–179

antigen detection 4, 176

assay characteristics 178, 179

complement fixation test (CFT) 179

DEAFF 177–178, 178

DNA detection 178, 180

dried blood spot test 178, 180

electron microscopy 177

enzyme immunoassays 178

IgG assays 179, 179

immune response detection 179–180

immunofluorescence 177, 179

PCR 17, 178, 180, 182

serological 179–180

specimens 175–176

virus detection 175–179

epidemiology 166, 166–167

incidence in HCWs 47

gastrointestinal disease 365

graft rejection association 175

hearing loss 173–174, 174

hepatitis 174

histopathology 176, 176–177

in hospitals, source of infections 47–48

host defences 170–172

immune response

cell-mediated 170–171, 171–172

detection 179–180

humoral 171

IgG antibodies see above

immunity 47, 179

imunization

passive T-cell immunotherapy 185

pre-exposure 184–185

see also cytomegalovirus (CMV) infection, vaccines

immunocompromised patients 175

clinical features 174–175

detection/samples 176

diagnosis 177

management 182–183

prevention 183

treatment 185

immunopathology 169–170

immunosenescent associated 175

incubation period 52, 170

infants 171, 174

infectious mononucleosis 174

management 180–183

nosocomial infection 47–48

pathogenesis 168–173, 169, 189

pathological effects 223

perinatal 180

clinical features 174

management 184

transmission 167

pneumonitis 174, 175, 183, 186, 190, 912

postnatal

clinical features 174

management 181–182

transmission 167–168

treatment 185–192

post-perfusion syndrome 168, 174

prediction 16

pregnancy 47, 168, 170, 176

counselling in 181, 182

detection/samples 176

hospital staff 47

IgM and screening 180

postnatal infection in women 181–182

prognosis 180–181

prophylaxis 183–184

prevention 183–185

of CMV transmission 183–184

rational/need for 183

primary 174, 182

vaccine protection 185

prognosis

after transplants 169, 169

congenital infection 180, 183

prophylactic treatment 186, 187–188

advantages 189

reactivation 167, 168, 174

recurrent 167

re-infection 167

vaccine protection 185

reinitis 190, 912

risk factors 168, 168–169

routes of infection 167–168

screening

antenatal 182

HCWs 47

neonatal 180

transplant recipients 170

acute infection treatment 189

management 183

prevention 183

prognosis 169, 169

prophylaxis 186, 187–188

treatment 186, 189, 190

treatment 185–192

early, active infections 186, 189–190

established disease 190–192, 191

late-onset disease 189

pre-emptive 186, 189, 189–190

suppression 186, 186

treatment/antiviral drugs 185–192, 186

monitoring 18

resistance 19, 170, 190

strategies for use 185–192, 186

see also ganciclovir (GCV)

vaccines 184–185, 185

cost savings 184

protection mechanisms 185

R&D 90, 91

viraeemia 169, 173, 175, 912

detection 176

cytopathic effect (CPE) 2

adenoviruses 478

arenaviruses 739, 740

CMV 161, 177, 177

enteroviruses 615

HIV 900

HSV 105

human parainfluenza viruses (HPIVs) 413–414, 417

human parvovirus B19 (B19V) 858

measles virus 551

rhinoviruses 498–499

rubella virus 565, 577

TTV 329

VZV 137, 137, 149

cytosine-β-D-arabinofuranoside, JC virus infection 847

cytosine-β-D-arabinofuranoside, JC virus infection 847

cytotoxic T cells (CTLs) 184

CMV infection 171

evasion, KSHV infected cells 261

HBV infection 292

HPV infections 419

HTLV-1 Tax-specific 887

lymphocytic choriomeningitis virus (LCMV) 742

see also CD8+ cells
Subject Index

Ebola haemorrhagic fever (contd.)
  Uganda 760, 770
  Zaire 759–760
past infections, virus persistence 766
pathogenesis and immunology 768–769
in pregnancy 764, 765
T-cell apoptosis 769
vaccines 766, 770
Ebola-like virus genus 756, 766, 768
Ebola virus (EBOV) 76, 766–767
 CIEBOV (Cote d’Ivoire) 756
epizootics (Reston virus) 760–761, 767–768
  genome 766
isolation/identification 765
monoclonal antibodies to 765, 770
perfusion 766
proteins 766–767
 REBOV (Reston) 756, 766
epidemiology 761
epizootics 760–761, 767–768
outcome and viraemia relationship 767, 768
serology 764
structure 756
reservoir (bats) 76, 762
SEBOV (Sudan) 756, 762, 766
  classification and diversity 607,
  characteristics
  Bornholm disease 612
  meningitis 610
  neonatal infection 612
  persistence in environment 49
  respiratory infections 613
see also encephalitis
  echinacea, rhinovirus infections 501, 501
  enteroviruses
    Bornholm disease 612
    characteristics 608
    classification and diversity 607, 607
    conjunctivitis 613
  ECV1, receptors 605
  ECV7 613
  ECV9, rubelliform rashes 613
  ECV11 613
  isolation/detection 615, 616
  meningitis 610
  neonatal infection 612
  persistence in environment 49
  respiratory infections 613
  side effects
  stimulants 613
  see also encephalitis
  eczema herpeticum 116
  eczema vaccinatum 634, 635
  efavirenz, HIV infection 925–926
elderly persons
coronavirus infections 521
increase, emerging infections and 71
infectious mononucleosis 209
influenza vaccination 404
RSV infection 450
SARS 522
electrodiathermy 818
electroencephalography (EEG)
  HIV encephalitis 119–120
  measles (SSPE) 544–545
  rashes 784, 791
  sporadic CID 951, 951
  electronic patient record (EPR) 22
electron microscopy (EM) 2,
  transmission 762, 763
  targets (cell types) 769
  improved detection methods 72, 72–74
  increased contact with vectors 72–74
  virus evolution 69–71
  mortality by year 69, 70
  SARS-CoV 61
  emtricitabine (FTC)
edentivigravir (ELV) 922
embryonated hens’ eggs, influenza virus
encephalomyelitis
  animal models 767
  electron microscopy (EM) 2,
  prevention 770
enfuvirtide (ENF)
  chronic fatigue syndrome
  dementia 458
  damage
  prevention/control 767
endocardial fibroelastosis, mumps 597
endothelial cell cultures, KSHV 254–255
endothelial cells
damage
  acute hepatitis 273
  CCHF virus 719
  congenital rubella syndrome 569
  Ebola haemorrhagic fever 769
  JC virus infection 836
  KSHV infection 252, 254
  KSHV persistence 255
  enfuvirtide (ENF)
  action 902
  infection 928
  enhanced green fluorescent protein (EGFP) 412
Encephalitis
  bovine spongiform see bovine spongiform
  encephalopathy (BSE)
  HHV-7 infection 232, 239
  HIV-associated (HIVE) 914
  infection
  myalgic (CFS) 458
  increased contact with vectors 72–74
  virus evolution 69–71
  mortality by year 69, 70
  SARS-CoV 61
encephalitis
  acute measles post-infectious 544
  alphaherpesviruses associated 656–661
  EEEV 657
  VEEV 659
  WEEV 658
  California 708
  congenital rubella syndrome (CRS) 573, 575
  enteroviruses causing 610
  herpes zoster complication 147
  HHFV-6 reactivation and 234–235
  HHV-7 infection 232
  HPIV causing 424
  HSV versus simplex virus (HSV)
  infection
  influenza 387
  Japanese see Japanese encephalitis
  measles 544
  side effects
  subacute sclerosing
  panencephalitis (SSPE)
  mumps 595, 596–597
  Murray Valley 690–691
  Nipah virus 76
  post-infectious
  HSV 120
  rubella 567
  post-transplant lymphoproliferative disease (PALD) 236
  post-vaccinal 634
  qualitative detection of genome 16
  rashes 788, 789
  Rift Valley fever virus 715–716
  Rocin virus 678–679
  Semliki Forest virus 661–662
  serological testing not indicated 21
  St Louis 687–688
  tick-borne see tick-borne encephalitis
  varicella (chickenpox) 144–145
  see also encephalomyelitis,
  meningoencephalitis
encephalomyelitis
  herpes simiae (B virus) 791
  post-vaccinal (PVE), rashes vs 791
  rashes 788
see also encephalitis
encephalopathy
  bovine spongiform see bovine spongiform
  encephalopathy (BSE)
  HHV-7 infection 232, 239
  HIV-associated (HIVE) 914
  influenza 391
  myalgic (CFS) 458
  increased contact with vectors 72–74
  virus evolution 69–71
  mortality by year 69, 70
  SARS-CoV 61
  emtricitabine (FTC)
  action 902
  infection 928
  enhanced green fluorescent protein (EGFP) 412
Entamoeba histolytica 161
entecavir
  hepatitis B 302–303
  resistance, HBV 302–303
  side effects 303
  side effects
  enteroviruses 357–358, 464–465, 475
  classification 357
  epidemiology 358
  gastroenteritis 471
  clinical features 358
  diagnosis 358
  diarrhoea 355
  pathogenesis 357–358
  prevention/control 358
  treatment 358
  genome 357
  immune electron microscopy (IEM) 358
  immune evasion 358
  PCR 358
  receptors/co-receptors 357–358
  replication 357–358
  structure 356, 357
see also adenoviruses
enterocyte dysfunction
  human orphan viruses see
  enteroviruses
Subject Index

virus persistence in environment 466
epidemic pleurodynia (Bornholm disease) 612
epidemiology of viral infections, resource-poor areas 23
epidermal growth factor receptor (EGFR) 811
epidermodysplasia verruciformis (EV) 813, 817
HPV types 812
squamous cell carcinoma (SCC) 813, 814
epithelial cells
KSHV persistence 255
rhinovirus infection 498, 499
epsilonretroviruses 872
Epstein-Barr virus (EBV) 199–221
BART (Bam A region transcript) 200–201, 214
B cell infection 200, 204, 206, 210
B cell transformation 201–202, 204
capsids 200
chromosomal integration 226
classification 199
coverancy 199
EBERs (EBV-encoded RNAs) 200, 215
EBNA 1–202, 211
IgG to 207, 207
EBNA 202, 204
EBNAs A, EBNA3B, EBNA3C 202
EBNA-LP 202, 204
EBNAs (EBV nuclear antigens) 201, 201–202
evolve 200
genes 202, 203
immediate-early, early and late 203
genome (dsDNA) 200, 201
glycoproteins 203–204
gp5 203
gp110 203–204
gp340/220 203, 218
gp350, vaccine development 218
handling in laboratory 204
host range and growth in vitro 204
immortalization 204
immune evasion 203, 205
infection process 206–207
KSHV (HHV-8) homology 245
latency 0 204
latency 1 204, 212
latency 2 204, 214
latency 3 204, 206, 212, 216
latency type 201
latent gene expression 201–202, 202
latent infections 200, 252
latent membrane proteins (LMPs) 202–203
latent proteins 201, 201–204
LMP 1 202–203, 214, 215
LMP2A and LMP2B 203, 214, 215
lytic cycle proteins 203
lytic gene expression 202, 203
membrane antigens (MAs) 203
morphology/structure 199–200, 200
physical characteristics 50
proteins and transcripts 200–201
receptors 204
in saliva 206, 215
shedding 205
strains (1 (A)/2 (B)) 200
terminal repeat (TR) sequences 200
Subject Index

Epstein-Barr virus (EBV) (contd.)
transmission 206
sexual 206
tumorigenesis mechanism 201–202, 204
tumorigenesis role 200
tumours 199, 206
VCA (viral capsid antigen complex) 203
antibodies 210
Epstein-Barr virus (EBV) infection
AIDS and 217–218
antibodies 209, 214
AIDS and 217–218
erythrocyte haemadsorption 982
ERK1/ERK2 pathway activation, JC virus 782
erboviruses 601
Equine torovirus (EToV) 511, 514, 515
etoposide 216
Erythroirus enterovirus 853, 854
lymphomas associated 199, 205, 206, 216, 916
nasopharyngeal carcinoma see nasopharyngeal carcinoma (NPC); EBV and normal seropositive individuals 205
oral hairy leukoplakia (OHL) 199, 218, 912
post-transplant lymphoproliferative disease (PTLD) 216–217
reactivation 205, 215
treatment, antivirals 210
vaccine development 218
X-linked lymphoproliferative syndrome and 216
Equine torovirus (EToV) 511, 514, 515
erythropoiesis 601
ERK1/ERK2 pathway activation, JC virus (JCV) 824
erythema infectosum (fifth disease) 856, 859–860
erythema multiforme 117, 636
erythrocyte haemadsorption see haemadsorption
Erythroirus 853, 854
Escherichia coli, enterocarbohydrate 522
ethylenediamine tetracetic acid (EDTA) 9
toposide 216
estravine (ETV), HIV infection 925–926
European bat lyssaviruses (EBLV) 778, 779, 782
EBLV-1
in bats 787
human infections 793
EBLV-1a 782
EBLV-1b 782
EBLV-2, human infections 793
EBLV-2a 782
infection incidence 783
European tick-borne encephalitis virus 673
Everglades virus 659, 660
evolution of viruses 69–71
exanthem subitum 232
experimental allergic encephalitis (EAE) 548
exposure-prone procedures (EPPs) 36, 37
external quality assessment (EQA), molecular amplification techniques 15
eye infections
adenoviruses 470, 472, 474–475
herpes zoster 146, 147, 153
HSV 117–119
HTLV-1 885, 891
Rift Valley fever virus 715
see also conjunctivitis; keratoconjunctivitis; retinitis
F
facial palsy
herpes zoster 146, 147
HSV reactivation 117
fanciclovir (Famvir)
herpes zoster 152
HSV infections 111, 113, 114, 116
structure 110
variella (chickenpox) 151
familial Alzheimer’s disease 949, 959
Far Eastern tick-borne encephalitis virus (FE-TEBV) 673, 692
fasciculation and elongation protein (FEZ1), JC virus 826
Fas-induced apoptosis 256, 259
fatal familial insomnia (FFI) 948, 958
Fc receptor
HSV producing 165
induction on fibroblasts by CMV 165
febrile convulsions
HHV-6 association 232
HHV-7 association 232
HPV causing 424
feline calicivirus 359
feline coronavirus (FCoV) 525
feline infectious peritonitis virus (FIPV) 517
fetal blood, rubella virus 580
fetal infections
parvovirus B19V 858, 864
see also congenital infections
fetal varicella syndrome 145, 152
fever
alphaherpesviruses associated 468–656
Crimean–Congo haemorrhagic fever 719
dengue fever 681
haemorrhagic see haemorrhagic fever
influenza 388
RSV infection 447
fever blisters (HSV) 113–114
fibroblasts
CMV growth 165, 177
virus isolation 2, 3
field mice, hantavirus transmission 721, 722
fifth disease 856, 859–860
Filoviridae 756, 766
filariviruses 755–775
‘Andromeda strain’ 755
animal models 767–768
classification 756, 766
ecology 761–763
gene (negative-sense ssRNA) 766–767
geographical distribution 755
GP1 and GP2 767
GP protein and sGP 766–767
historical aspects 755
infections
clinical spectrum of disease 763–764
control 769–770
epidemics 756–760
epidemiology 756–761
laboratory diagnosis 764–765
management 765–766
outbreaks 76, 755–756, 756–761, 770
pathogenesis and immunology 768–769
prevention 764–765
see also Ebola haemorrhagic fever;
Marburg haemorrhagic fever
NP and L proteins 767
outcome and viraemia relationship 767, 768
replication 766
serology 768
structure 756, 766
transmission and risk factors 763
vaccines 770
virus-like particles (VLPs) 767
VP24 767
VP30 and VP35 767
Zaire strain 755–756
see also Ebola virus (EBOV); Marburg virus (MARV)
Flaviviridae 73, 309, 321, 669
Flavivirus 669, 670
flaviviruses 669–698
antigenic classification 672, 673–674
antigenic properties 671–672
biophysical/biochemical properties 670–671
clades 672
C protein 671
distribution (geographical) 669
E protein 671, 676, 682, 685, 687
genetic properties 671–672
gene (positive-sense ssRNA) 670–671
organization 671, 671
hosts 669
infections
clinical features 670
diagnosis 670
laboratory diagnosis 671
prevention and therapy 670
JE serogroup 688
lipids 671
mosquito-borne 672, 673
Subject Index

neurotropic 672
new/emerging 73
‘no known vector’ group 672, 678
non-neurotropic 672
nonstructural proteins (NS1–5) 671
phylogenetic analysis 672
pMP protein 671, 676, 685
replication 670
structure/morphology 670
subgroups 671
tick-borne 672, 673, 691–694
groups 691
see also tick-borne encephalitis
transmission 669
unassigned subgroup 673, 678–679
see also dengue virus; West Nile virus
(WNV); yellow fever virus; other specific viruses (see pages 673–704)
Flexal virus 734
flower cells, ATLL 884, 885
fluorescence-based immunosassay, viral antigen
detection 4, 4
fluorescence in situ hybridization (FISH),
HHV-6 integration 226, 227
fluorescent antibody-to-membrane antigen
(FAMA), VZV 150
fluorescent antibody virus neutralization (FAVN)
test, rabies 786
fluorescent labels 4
focal adhesion kinase (FAK) 256
follicular dendritic cells (FDCs)
HIV infection 904
prions in 947
food
hepatitis A transmission 276
hepatitis E transmission 280
norovirus/sapovirus transmission 362
Fort Morgan virus (FMV) 644, 658
Fort Sherman virus 702, 707
foscarnet
CMV infection 185
acute infection treatment 189
established disease 190–192, 191
HHV-6 and HHV-7 240
KSHV infection 263
structure 110
toxicity 185, 188
foxies, rabies 781, 782, 801
fruit bats
Ebola virus reservoir 762, 770
rabies 783
Tacaribe virus 734
virus vectors 75
see also bats
FSME-IMMUN 694
FTC see emtricitabine (FTC)
FUT2 allele (secretor gene), norovirus infection
resistance and 362
G
Gabapentin, herpes zoster pain 153
GAD56 575
Gamma-2 herpesviruses
lineages 246, 247
RV-1 and RV-2 lineages 246, 247
Gammaherpesvirinae 95, 96, 199
biological properties 97
 gammaretroviruses 872, 872
novel 77
Gammatorquevirus 326, 327
ganciclovir (GCV)
adenovirus infections 482
CMV infection 185, 189
established disease 190–192, 191
prophylaxis 186, 187–188
resistance 170, 190
genital CMV infection 181
HHV-6 infection 240
HSV infections 111
KSHV infection 263
mechanism of action 183
oral 186
structure 110
 toxicity 181, 185
ganglia, latent VZV infections 141, 142, 146
gangliosides, BKV receptors 825
Gapamavirus
206
gastroenteritis, viral
detection 16
noroviruses and sapoviruses 358–363
detection methods 356
epidemiological patterns 356
genotypic assays 364–366
types not regularly associated 364–366
see also individual viruses
see also diarrhoea
GBV (GB virus) 322
in animals 322
cell culture 323
genome 322–323, 323
GBV-A 321, 322, 669, 670
in animals 322
detection 73
genome 322–323, 323
GBV-B 321, 322, 669, 670
in animals 322
cell culture 323
detection 73
GBV-C 321–325, 322, 669, 670
in animals 322
cell culture 323
detection 73
E2 protein 322–323
genome 322–323, 323
genotypes 322–323
glycoproteins 325
HCV co-infection 324
in healthy population 323–324
history 321–322
HIV co-infection 324–325
infection (human) 324–325
internal ribosome entry site (RES) 322
PCR 323–324
phylogenetic analysis 322–323
replication 323
site 323
transmission 324
viraemia, in children 324
GB virus C/Hepatitis G virus see GBV-C
GDD motif, HCV 310
GenoExpert System 15
gene therapy
adenoviruses as vectors 482
HD-TET-IFN, GBV-B growth inhibition 323
troviruses as vectors 869, 872–873
genetic microsatellite markers, EBV and
Hodgkin’s disease 215
genetic reassortment of viruses 71, 86
GenHecavac vaccine 305
genital cancers, HPV and 813, 814–815
/genital infections, HSV see herpes simplex virus
(HSV) infection
/genital ulcers, HSV 114, 115, 115
genital warts 816, 817
HPV and 814, 816, 817
as KSHV risk factor 250–251
genome (viral)
qualitative detection 16
sequencing 18
genomic drift, rotaviruses 345
genomic shift, rotaviruses 345
genotypic assays
antiretroviral drug resistance 918, 919
antiviral resistance detection 19, 19–20
genotyping of viruses 17
German measles see rubella
geminal-centre hyperplasia 254
Germiston virus 702, 707
Gerstmann–Str¨aussler syndrome (GSS) 939, 948, 949, 957, 959
see also prion diseases
Getah virus (GETV) 644
Giant multinucleated cells see multinucleated
giant cells
giant pronormoblasts, human parvovirus B19
(B19V) 858, 858
glandular fever see infectious mononucleosis
(IM)
glucoma, congenital rubella syndrome 574
glial cells
JC virus growth 824, 826, 842
rabies virus infection 784
Global Alliance for Vaccines and Immunization
(GAVI), yellow fever vaccine 678
Global Eradication Programme, smallpox 634
glucoapticostroids see corticosteroids
gluco transport protein (GLUT-1), HTLV-1
receptor 876–877
α-glucosidase inhibitors, endoplasmic reticulum,
HPIV infection treatment 430
glutamic acid decarboxylase, enterovirus protein similarity 614
glycosaminoglycans, HSV attachment 97
glycyrhizic acid, KSHV infection 263
gpELISA, VZV 150–151
Graham 293 cells 357
green monkey disease 755
GRO-α (growth-related oncogene-α) 417
ground squirrel hepatitis virus (GSHV) 284
growth hormone deficiency, congenital rubella syndrome 575
Guama virus 702, 710
Guaranito virus 734, 750–751
Guarnieri bodies 632
Guaroa virus 702, 710
GU-DANA, HPIV infection treatment 429
Guillain–Barre syndrome
EBV 209
d herpes zoster 147
HPIV 424
influenza 391
rabies vaccine side effect 800
West Nile virus 690
guinea pigs, VZV pathogenicity 139
gut-associated lymphoid tissue (GALT), HIV
infection 905, 910–911
Gyrovirus 332

H
H-2 region, LCMV infection 743
HAART 921
adenovirus infections in HIV infection 477
CMV infection treatment and 189–190
developing countries 930
HIV infection
CD4 T cell count before 916
effects on morbidity/mortality 916
initiation recommendations 917
vertical transmission prevention 930
viral load reduction 917
in KHSV infections 263
monitoring 17
in progressive multifocal leukoencephalopathy 840, 841, 847
haemadsorption 2, 3
HPIV infections 426
influenza virus 392
haemagglutination inhibition (HAI) see individual infections
haemagglutinin protein
influenza virus see influenza virus
light 540
measles virus see measles virus (MV)
parainfluenza viruses see human parainfluenza viruses (HPIVs)
Haemagogus mosquitoes
Mayaro virus transmission 655
yellow fever transmission 674
haematopoietic stem cell transplant (HSCT) recipients
adenovirus infections 475–476, 476
HHV-6 infection 235–236, 240

Subject Index

haemorrhagic fever
Argentine haemorrhagic fever 746
hantaviruses 724
Lassa fever 748–749
Marburg/Ebola haemorrhagic fevers 764
haemorrhagic conjunctivitis, acute, adenovirus serotypes 472
haemorrhagic cystitis see cystitis, haemorrhagic haemorrhagic diathesis
dengue haemorrhagic fever 682
Ebola and Marburg haemorrhagic fevers 768–769
Kyasunaru Forest disease virus 695
yellow fever 676
see also haemorrhagic derangement
haemorrhagic fever
arenaviruses 733
see also Argentine haemorrhagic fever (AHF); Bolivian haemorrhagic fever; Lassa fever
CDC guidelines for management 770
Chakungunya virus infection 651
cytokines and inflammatory mediators 743
tick-borne encephalitis viruses 691
haemorrhagic fever with renal syndrome (HFRS) 73, 703, 721–726
Balkan 724
causative virus 721, 722
clinical forms 723–724
Far Eastern 724
incubation and clinical features 724
mild (rat-borne) 724
treatment and prevention 725
see also Hantaan virus; hantaviruses
haemorrhagic nephropathy 721
haemostatic derangement
Crimean–Congo haemorrhagic fever 719
Rift Valley fever virus 715, 716
see also coagulation cascade; haemorrhagic diathesis
hairpin oligonucleotides (HIVs)
hairy cell leukaemia (HCL) 876, 884
hand, foot and mouth disease 612–613
hand washing
adenovirus infection prevention 466
CMV infection prevention 48
RSV transmission prevention 62
Hantaan-like viruses 723
Hantaan virus 73, 704, 721–726, 725
discovery 721–722
subtypes 722
Hantavirus 699, 721–726
members and vectors 704
hantavirus cardiopulmonary syndrome 721
hantaviruses 721–726
antibody cross-reactivity 726
biological properties 700
cell culture difficulties 700
clinical infections 723, 724, 725
distribution 723
emerging 75, 723
detection 75
New world, distribution 75
infection route 723
investigation of infections 726
pathogenesis of syndromes 725
renal disease due to see haemorrhagic fever with renal syndrome (HFRS)
respiratory disease due to see hantavirus pulmonary syndrome (HPS)
rodent-borne 75
serological classification 723
transmission 723
hantavirus pulmonary syndrome (HPS) 73, 703, 721, 722
clinical features 725
outbreaks 722–723
see also hantaviruses; Sin Nombre virus
Hazaras virus 700
HBsAg, HBcAg, HBeAg see under hepatitis B virus (HBV)
HCoV-229E see human coronavirus 229E (HCoV-229E)
HCoV-OC43 see human coronavirus OC43 (HCoV-OC43)
health-care workers (HCWs)
adeno virus infection 61
blood-borne virus transmission from patients 32–36
to patients (from HCWs) 36–38
prevention of exposure 30
CMV infection 47–48, 182
HBV monitoring 18
HSV infection 53–54
influenza 58–60
measles 44–45
mumps 45–46
norovirus infections 54–55
parainfluenza virus infection 60–61
parvovirus B19 infection 56–58
respiratory virus infections 58–63
rotavirus infection 56
RSV infection 62–63
rubella 46–47, 584
SARS 61–62
vaccination 34, 44
rubella and MMR 584
varicella 51, 53
VZV infection 48–53
Health Protection Agency (UK) 21
hearing defects, congenital rubella syndrome 173–174, 174, 181
congenital rubella syndrome 570, 572
574–575
mumps 597
heart defects, congenital rubella syndrome (CRS) 572, 573
heart disease, enterovirus infections 610–612
hepatitis A virus (HAV) 273, 276–278
hepatitis A 275–280
Henderson–Patterson bodies 636
Hendra virus 75, 410, 424
Hemiparasites 76
Hepaderivius 309, 667, 670
Hepadnaviridae 284
Hepadnavirus 286
hepatitis 273
acute hepatitis D 309
hepatitis B 291, 297, 313
autoimmune chronic 279, 313
cholestatic 279
chronic 273, 274–275
cellular features 275
CMV causing 174
delta see hepatitis D
delta epidemic see hepatitis E
fulminant 274, 275, 291
acute hepatitis D 309
hepatitis B 291, 297, 309
liver function tests 275
lobular 274
mortality 275
non-A, non-B, virus 273–274
non-A, non-B, non-C 273–274
mortality 275
non-A, non-B, non-C see hepatitis E
non-A, non-B, virus see hepatitis C virus (HCV)
pathology 273–275
post-transfusion, hepatic viruses 670
testing strategy 21, 21
hepatitis A 275–280
age incidence 276
clinical course 278–279
diagnosis and serological profile 278, 278
food-borne outbreaks 276
incubation period 275
passive immunization 279
pathogenesis 278
prevention/control 279
vaccines/vaccination 86, 279–280
attenuated vaccines 280
inactivated vaccines 279–280
infection control in Israel 89
hepatitis A virus (HAV) 273, 276–278
antibodies 275, 278
attenuation 277, 280
capsid antigen 275–277, 278
cell culture 277–278
characteristics 274
genome (positive-sense RNA) 276–277
mutations, vaccines 280
organization 277, 277
genotypes 278
IgM to 278
proteins 277
serotype 277
shedding 276
stability 277
structure 276, 276–277
transmission 276
hepatitis B 282–307
acute
diagnosis 290–291
serology 288, 288
treatment 301
antibodies 295
anti-a 285
anti-HBc 31, 286, 288, 290, 290
anti-HBe 288, 288, 289, 290, 290, 291, 298
anti-HBs 288, 290, 290
in health-care workers 34
neutralizing 295
antiviral therapy 297
adefovir dipivoxil 301–302
clevudine 304
emtricitabine (FTC) 304
tenofovir (TDF) 302–303
goals and endpoints 298
HBcAg-negative disease 297, 298–299,
300, 301, 302, 303
HBcAg-positive disease 297, 298, 300,
301, 302, 303
IFN-a 297, 299–300
lamivudine 301
monitoring by DNA levels 17
new agents 304–305
nucleoside/nucleotide analogues 300–301,
306
telbivudine 303
tenofovir 303–304
antiviral therapy resistance 19, 299
adefovir 302
emtricitabine 304
tenofovir 302–303
lamivudine 299, 301
telbivudine 303
autotransfusions 290
breakthrough infections 295
chronic 274, 283–284
diagnosis 290, 291–292
HBcAg-negative 291–292, 298–299, 300,
301, 302
HBcAg-positive 36, 291, 292, 297–298,
300, 301, 302
hepatocellular carcinoma 306–307
IFN treatment 299–300
phases 288–289, 291
remission 291
seroconversion, anti-HBc 288–289, 291,
298
serology 288, 288–289
treatment 297–299, 301
cirrhosis development 292
diagnosis 283
nucleic acid testing 31
diagnostic assays 290, 290
epidemiology 282–283, 283
eradication 297
fulminant 291, 297, 309
HBcAg-positive HCWs 36
hepatocellular carcinoma and see hepatocellular carcinoma (HCC)
HIV co-infection 914–915
prevention 290, 303–304
immune complex formation 290
immune response 292–293
immunocompetent 292, 293
immunity, maintenance 294–295
immunization
active 293–294
DNA-based 306
hepatitis D prevention 308
indications (UK) 296–297
kinetics 294–295
passive 293
recommendations 293–294, 295
site and response 294
see also hepatitis B, vaccines
immunoprophylaxis (combined) 296
neonatal infections 293
occult 292
pathogenesis 292–293
perinatal infections 283, 293
prevention/control 293–296
seroconversion 288–289, 291, 298
serological profiles 288, 288–289, 290
transfusion transmitted, reduction
strategies 31
transplant recipients, treatment 299
transplantation
antivirals see hepatitis B, antiviral therapy
biological response modifiers 305
immunotherapy 305–306
vaccines 293–294
administration site and response 294
boosters 295
CY-1899 305
first-generation 293, 296
GenHevac vaccine 305
for health-care workers 34
multiple sclerosis and 90
nonresponse 294
recombinant DNA 293, 294, 296
response to 34
second-generation 293, 294
Theradigm HBV tm 305
third-generation 296
see also hepatitis B, immunization
hepatitis B immunoglobulin (HBIG) 293, 296
hepatitis B virus (HBV) 273, 284–288
antibodies 295, 296
antigens 274, 292
blood donation testing 30
carriers 36–37, 284
HDV superinfection
immunotherapy 305–306
vaccines 293–294
administration site and response 294
boosters 295
CY-1899 305
first-generation 293, 296
GenHevac vaccine 305
for health-care workers 34
multiple sclerosis and 90
nonresponse 294
recombinant DNA 293, 294, 296
response to 34
second-generation 293, 294
Theradigm HBV tm 305
third-generation 296
see also hepatitis B, immunization
hepatitis B immunoglobulin (HBIG) 293, 296
hepatitis B virus (HBV) 273, 284–288
antibodies 295, 296
antigens 274, 292
blood donation testing 30
carriers 36–37, 284
HDV superinfection
immunotherapy 305–306
vaccines 293–294
administration site and response 294
boosters 295
CY-1899 305
first-generation 293, 296
GenHevac vaccine 305
for health-care workers 34
multiple sclerosis and 90
nonresponse 294
recombinant DNA 293, 294, 296
response to 34
second-generation 293, 294
Theradigm HBV tm 305
third-generation 296
see also hepatitis B, immunization
hepatitis B immunoglobulin (HBIG) 293, 296
hepatitis B virus (HBV) 273, 284–288
antibodies 295, 296
antigens 274, 292
blood donation testing 30
carriers 36–37, 284
HDV superinfection
immunotherapy 305–306
vaccines 293–294
administration site and response 294
boosters 295
CY-1899 305
first-generation 293, 296
GenHevac vaccine 305
for health-care workers 34
multiple sclerosis and 90
nonresponse 294
recombinant DNA 293, 294, 296
response to 34
second-generation 293, 294
Theradigm HBV tm 305
third-generation 296
see also hepatitis B, immunization
hepatitis B virus (HBV) (contd.)
HBcAg 274, 284, 286, 292
anti-HBc antibodies 31, 286, 288, 290, 290
variants 293
HBsAg 284, 286, 289, 290, 290, 292
anti-HBs antibodies 288, 288, 289, 290, 290, 291, 298
 carriers 284
chronic hepatitis 290, 291
loss, chronic hepatitis 288–289, 291, 298
prediction of transmission by 18
HBVAg 274, 282, 284, 285–286
acute hepatitis diagnosis 290, 290
adw, adr, ayw, ayr 285–286, 296
antigenic determinants (‘a’) 285, 286
anti-HBs antibodies 288, 290, 290
G145R mutant 295, 296
hepatocellular carcinoma and 306, 307
interpretation of serological tests 7
persistence, chronic hepatitis B 283–284
variants 293
pre-S proteins 285
pre-S1 protein 285, 296
persistent infections 274–275, 312
post-exposure prophylaxis 35
prevention 316
vaccines 310, 316
hepatitis C virus (HCV) 273, 280–282
antibodies (IgG) and 281–282
clinical features 282
diagnosis and serology 281–282
HCV co-infection 312, 315
HIV co-infection 914–915
immunization 282
incubation period 280
pathogenesis 281
pathology 281
sporadic, in industrialized countries 282
vaccines 282
hepatitis E virus (HEV) 273, 280–281, 281
characteristics 274
detection 73
vaccines 282
hepatitis G virus see GBV-C
hepatitis viruses 273–320
hepatocellular carcinoma (HCC) epidemiology 306
hepatitis B and 306–307
HBV DNA 306–307
oncogenesis mechanisms 307
hepatitis C and 312, 315
HTLV-1 and 884
hepatitis D virus (HDV) 273
characteristics 274
hepatitis E virus (HEV) 273, 280–281, 281
characteristics 274
detection 73
genome (positive-sense RNA) 280, 281
organization 281, 281
vaccines 282
hepatocytes acute hepatitis 273
‘ground-glass’ 274
lysis, HBV infection 292
regeneration 274
Hepatitisviruses 277
hepatotropics 601
herbal medicines, rhinovirus infections 500
herd immunity 82
CMV immunization 184
mumps 46
herpangina coxsackievirus group A 612
differential diagnosis 112–113
herpes febrilis 113–114
herpes gladiatorum 116
herpes labialis 113–114
herpes simiae (B virus) encephalomyelitis 791
herpes simplex virus (HSV) 95–131
antigens detection 2–3, 4
VZV cross-reaction 150
assembly 99
attachment/infection process 97–98

Subject Index

organ/tissue transplantation 32
carriers 312
chronic 274–275, 312
pathology 274, 274–275
treatment 312–314
chronic fatigue in 614
diagnosis/detection 273, 311–312
in blood products 31
enzyme immunosassay (EIA) 311–312
in health-care workers 38
initial, cDNA expression library screening 72
PCR and RT-PCR 12, 31, 31
sensitivity 15
serological test interpretation 311–312
epidemiology 310–311
hepatocytes 274, 275
HDAg 307, 308, 309
variants 295–296
anti-HBc antibodies 31, 286, 288, 290,
chronic hepatitis 288–289, 291, 298
prediction of transmission by 18
HBVAg 274, 282, 284, 285–286
acute hepatitis diagnosis 290, 290
adw, adr, ayw, ayr 285–286, 296
antigenic determinants (‘a’) 285, 286
anti-HBs antibodies 288, 290, 290
G145R mutant 295, 296
hepatocellular carcinoma and 306, 307
interpretation of serological tests 7
persistence, chronic hepatitis B 283–284
variants 293
pre-S1 and pre-S2 domains 285, 296
time course 288, 288, 290, 290
variants 295–296
HBVAg-positive HCVs 37
HDV co-infection 308
helper function for HDV 307–308
hepatocellular carcinoma and see hepatocellular carcinoma (HCC)
immune evasion 292, 293
oncogenesis mechanisms 307
open reading frames 284, 285, 286
p22 (core protein) 286
polymerase 286
mutants, drug resistance 301, 302, 303, 304
nucleoside analogue action 300–301
post-exposure prophylaxis 35, 35
precore variants/mutant 291
pre-S1 protein 285, 296
pre-S proteins 285
replication 286–288, 289, 297–298
HDV interference 309
RNA intermediate 286–287, 287
structure 284, 284–285
surface antigen see hepatitis B virus (HBV), HBsAg
transformation by 307
transmission 283
HCW-to-patient 36–37
patient-to-HCW 33, 35, 55, 56
patient-to-patient (blood-borne) 31
perinatal 283, 293
prevention 36–37
sexual 283
transmissions, reduction strategies 31
variants 291, 295–296
screening 295–296
X gene (transcriptional transactivator) 307
hepatitis C 309–316
acute, treatment 312
alcohol consumption and 312–313
antibodies 311–312
antibody detection 7, 311–312
clinical features 309
diagnosis and serology 308–309
epidemiology 308
HBV co-infection 308
pathogenesis 309
treatment and prevention 309
hepatitis D virus (HDV) 273
characteristics 274
genome (RNA) 308
HBV carrier superinfection 308–309
HDAg 307, 308, 309
small and larger forms 308
replication 307–308, 309
structure 308
hepatitis E 280–282
antibodies (IgM) 281–282
clinical features 282
diagnosis and serology 281–282
immunization 282
incubation period 280
pathogenesis 281
pathology 281
sporadic, in industrialized countries 282
vaccines 282
hepatitis E virus (HEV) 273, 280–281, 281
characteristics 274
detection 73
genome (positive-sense RNA) 280, 281
organization 281, 281
vaccines 282
transmission 280, 282
hepatitis G virus see GBV-C
hepatitis viruses 273–320
hepatocellular carcinoma (HCC) epidemiology 306
hepatitis B and 306–307
HBV DNA 306–307
oncogenesis mechanisms 307
hepatitis C and 312, 315
HTLV-1 and 884
TTV association 330
hepatocytes acute hepatitis 273
‘ground-glass’ 274
lysis, HBV infection 292
regeneration 274
Hepatitisviruses 277
hepatotropics 601
herbal medicines, rhinovirus infections 500
herd immunity 82
CMV immunization 184
mumps 46
herpangina coxsackievirus group A 612
differential diagnosis 112–113
herpes febrilis 113–114
herpes gladiatorum 116
herpes labialis 113–114
herpes simiae (B virus) encephalomyelitis 791
herpes simplex virus (HSV) 95–131
antigens detection 2–3, 4
VZV cross-reaction 150
assembly 99
attachment/infection process 97–98
herpes zoster (contd.)
  immunocompromised patients 146–147
  treatment 153
  incidence 146
  latency sites 141, 146
  meningitis, encephalitis and myelitis 147
  neuralgia 133, 139, 147
  ophthalmic 146, 147, 153
  pain 147, 152, 153
  animal model 139
  pregnancy 147
  prevention 153–156
  prophylactic drugs 154
  reactivated VZV vaccine and 152
  skin lesions 140,
  reactivated VZV vaccine and 53
  treatment 152–153
  of pain 152, 153
  vaccines 156
  see also under varicella zoster virus (VZV)
  VZV transmission to HCWs 49
  see also varicella zoster virus (VZV),
  reactivation
  herpetic gingivostomatitis 54, 112–113
  herpetic keratitis 117–119,
  118
  herpetic whitlow 54, 104, 116,
  118
  prevention 117
  HERV-K 872
  HERV-W 872
  Highlands J virus (HIV) 644, 658
  highly active antiretroviral therapy see HAART
  histamine, rhinovirus infections 494
  histocompatibility antigens (HBGAs) 359, 362
  histology 2
  HIV 76, 897–938
  ABOBECE 3C effect 901, 902
  APOBECC3, polymorphisms 903
  blood donation testing 30
  CD4 T cell infection 901, 902, 904
  cell types infected 901, 904
  CMV interactions 172–173
  CNS as sanctuary site for 914
  coreceptors 898, 901–902, 903, 904
  culture and isolation 900
  cytopathic effect 900
  in dendritic cells 904
  dynamics 903–904
  entry and uncoating 902
  inhibitors 921, 928–929
  env gene 901
  gag gene 900
  genes and proteins 900–901
  genetic variation 902, 905
  genotyping, drug resistance 918, 920
  gp41 902, 905–906
  gp120 901, 902, 905–906
  G-to-A mutations 902
  infection see HIV infection
  infection process 901–903
  integrase
  inhibitors 921, 929
  LEDGFp75 and 902
  life cycle, drug action 922
  long terminal repeat (LTR) 901
  molecular epidemiology 900
  mRNA production 902
  mutation 70–71
  origin 897
  p17 protein 900
  p24 capsid antigen 901
  persistence 904
  phylogenetics 900
  pol gene 901
  pre-integration complexes (PIC) 901, 902
  protease 926
  inhibitors see protease inhibitors
  proviral DNA integration 902, 904
  quasispecies 904, 905, 918
  rapid evolution/changes 881, 902, 905, 918
  receptors (CD4) 901–902, 904
  recombination between strains 918
  replication 900–903, 901–903, 918
  CD4 T-cell loss and 905
  error-prone 881, 902, 918
  inhibition 923
  reporter gene 918–919
  sites 904, 910–911
  reservoirs (CD4 T cells and dendritic
  cells) 904
  restriction factors, polymorphisms 903
  Rev and Rev-response elements (RRES) 901
  reverse transcriptase 902, 918
  inhibition see nucleoside/nucleotide reverse
  transcriptase inhibitors (NRTIs)
  reverse transcription 902
  RNA detection 907, 909
  SP1, MA and CA proteins 903
  structure 904
  tat/gene/protein 831, 901
  transmission 899
  blood, infection risk 931
  HCW-to-patient 38
  patient-to-HCW 33, 33, 35–36, 36
  prevention 925–932
  sexual 899, 930, 931
  transfections 31
  vertical 18, 899, 929–930
  TRIM5 proteins 902, 903
  tropism 904, 920, 920
  tropism assays 920, 920
  V3 loop 904, 920
  Vif 901
  viral fitness 900, 902–902
  viral load 910
  assays 917–918
  drug monitoring/initiation 917–918
  predictive of CD4+ cell decline 17
  predictive of transmission 18
  set-point 910
  virion production 902–903
  Ypr and Vpu 901
  HIV-1 870
  discovery 897
  genome 898
  group M 897, 898, 900
  long terminal repeat (LTR) 831
  N group 897
  nomenclature 870, 876
  nonsyncytium inducing (NSI) 897–898
  origin 76, 897–898
  outlier (O) group 897
  R5 viruses (CCR5 co-receptor) 898, 904
  R5X4 (dual-tropic) 898
  subtypes A–D 900
  subtypes/clades 897, 900
  syncytium inducing (SI) 897, 901
  tat protein 831
  transactivation of human
  polyomaviruses 830–831
  X4 viruses (CXCR4 co-receptor) 898, 904, 906
  HIV-2 870
  discovery 897
  genome 898
  origin 76
  HIV-associated encephalopathy (HIVE) 914
  HIV infection 897–938
  ACTG 076 protocol 931
  antibodies detection 7, 906–907
  maternal 908
  neutralizing, passive therapy 932
  non-neutralizing 905
  salivary, testing 907
  screening 906
  antigens, detection 906
  antiviral therapy 921, 921–929
  classes and individual drugs 921, 921–929
  historical perspective 916–917
  monitoring 17
  mortality/morbidity reduction 916
  resistance 19, 20, 918–920
  targets 901–903
  see also antiretroviral drugs; specific drug
  groups
  asymptomatic phase 911–912
  CD4:CD8 ratio 911
  CD4 T-cell apoptosis 905
  CD4 T-cell depletion 904–905, 910
  cell-mediated immunity 905
  chronic diarrhoeal disease 365
  clinical features 909, 909–916, 911
  CMV infection 172–173, 912
  dissemination to lymphoid organs 905
  encephalopathy 914
  epicentre of epidemic (DRCongo) 897, 900
  epidemiology 72, 899–900
  GBV-C co-infection 324–325
  geography and prevalence 899, 899
  HBV co-infection 303–304, 914–915
  HCV co-infection 914–915
  herpes zoster and 148
  history 897–898
  host genetic determinants 903
  HSV-2 with 115, 912–913
  HIV with 127
  HTLV co-infection 891
  immune activation, T-cell depletion 905
  immune responses 905–906
  immunological phases 909, 909–916
  JCV co-infection 831, 837, 840, 844, 914
  KSHV transmission/infection and 250, 252,
  254
  laboratory diagnosis 906–909
Subject Index

Hodgkin Reed–Sehrtberg (HR-S) cells 215
Hodgkin’s disease (HD) 215
EBV and 199, 206, 215
HHV-6 association 231
in HIV infection 915
Hokkaido virus 704
homosexual men
CMV infection 166, 168
immunization 185
enteric coronavirus infections 522
HIV infection 897, 899, 900
KS/H transmission 250, 252
horses
EEEV 656, 657
Hendra virus 75
VVEV 659, 660
WEEV 658
West Nile virus 688, 689
hospital-acquired virus infections see
nosocomial infections/transmission
host defense mechanisms
host factors, outcome affected by 1
HPIV infections see human parainfluenza
viruses (HPIVs)
HTLV 76, 875–896
assembly 877–878
budding and release 889, 889
bZIP factor/protein (HBZ) 871, 879
pre-exposure prophylaxis 932
primary infection 910–911
vaccines 932
VZV co-infection 914
see also AIDS

HLA
dengue haemorrhagic fever (DHF) 683
Hodgkin’s disease 215
nasopharyngeal carcinoma 214
see also major histocompatibility complex (MHC)
HLA A2, hepatitis B immunotherapy and 305
HLA-E, CMV infection 172
specific cytotoxic T cells 887
T cell immortalization 886
transactivated genes 886, 887, 887
transmission 876, 883–884
blood products 884, 889
mother-to-child 883, 891
prevention 891
sexual 883–884
U3 region 877
variation and mutation rates 880–881
HTLV-1 76, 870–871, 875
antibodies 877
blood donation testing 31
as carcinogen 884
CD4+ lymphocyte infection 876, 887, 889
cell-to-cell transfer 888, 889
cellular and viral replication 888
diagnosis 879–880, 880
discovery 869
diseases associated 75, 884–886
epidemiology 881–883
HHV-6 association 889
HTLV-1-associated myelopathy (HAM) 876
see also HTLV-associated myelopathy/tropical spastic paraparesis (HAM-TSP)
HTLV-1(MEL) 880
HTLV-2 76, 871, 875
CD4+ lymphocyte infection 876
diseases associated 876, 886
epidemiology 882, 883
 identifiers 887
proteins 879
transmission 881
types a, b, c 880
HTLV-3 see HIV
HTLV-4 875, 876
HTLV-associated myelopathy/tropical spastic paraparesis (HAM-TSP) 76, 886
differential diagnosis 885
epidemiology 883
HLA associations 889
pathogenesis 887, 889
risk in HTLV-1 infections 884
treatment 890–891
HTLV infections
antibodies 889
maternal 883
diagnosis 879–880
see also adult T-cell leukaemia-lymphoma (ATLL); HTLV-associated myelopathy/tropical spastic paraparesis (HAM-TSP)

advantages/disadvantages 908
CDC definitions 907
children 908–909
confirmatory tests 906–907
early vs established infections 908
enzyme immunoassay (ELA) 906, 908
p24 antigen detection 4
PCR 908
rapid anti-HIV antibody assays 907–908, 908
recent infection detection 907, 908
screening tests 906
sensitivity 15
Western blotting 906–907
lupus 217–218, 915–916
malignancies associated 915–916
measles vaccination 554
malignancies associated 915–916
lymphomas 217–218, 915–916
major histocompatibility complex (MHC)
nasopharyngeal carcinoma pathogenesis 214
Hodgkin’s disease 215
HIV, transmission 897
see also HCV
host defense mechanisms 876, 886
host factors, outcome affected by 1
HPIV infections see human parainfluenza
viruses (HPIVs)
HTLV 76, 875–896
assembly 877–878
budding and release 889, 889
bZIP factor/protein (HBZ) 871, 879
pre-exposure prophylaxis 932
primary infection 910–911
vaccines 932
VZV co-infection 914
see also AIDS

HLA
dengue haemorrhagic fever (DHF) 683
Hodgkin’s disease 215
nasopharyngeal carcinoma 214
see also major histocompatibility complex (MHC)
HLA A2, hepatitis B immunotherapy and 305
HLA-E, CMV infection 172
specific cytotoxic T cells 887
T cell immortalization 886
transactivated genes 886, 887, 887
transmission 876, 883–884
blood products 884, 889
mother-to-child 883, 891
prevention 891
sexual 883–884
U3 region 877
variation and mutation rates 880–881
HTLV-1 76, 870–871, 875
antibodies 877
blood donation testing 31
as carcinogen 884
CD4+ lymphocyte infection 876, 887, 889
cell-to-cell transfer 888, 889
cellular and viral replication 888
diagnosis 879–880, 880
discovery 869
diseases associated 75, 884–886
epidemiology 881–883
HHV-6 association 889
HTLV-1-associated myelopathy (HAM) 876
see also HTLV-associated myelopathy/tropical spastic paraparesis (HAM-TSP)
HTLV-1(MEL) 880
HTLV-2 76, 871, 875
CD4+ lymphocyte infection 876
diseases associated 876, 886
epidemiology 882, 883
 identifiers 887
proteins 879
transmission 881
types a, b, c 880
HTLV-3 see HIV
HTLV-4 875, 876
HTLV-associated myelopathy/tropical spastic paraparesis (HAM-TSP) 76, 886
differential diagnosis 885
epidemiology 883
HLA associations 889
pathogenesis 887, 889
risk in HTLV-1 infections 884
treatment 890–891
HTLV infections
antibodies 889
maternal 883
diagnosis 879–880
see also adult T-cell leukaemia-lymphoma (ATLL); HTLV-associated myelopathy/tropical spastic paraparesis (HAM-TSP)
HTLV infections (contd.)
edemiology 881–883, 882
HIV co-infection 891
pathogenesis 886–889
autocrine loop theory 887
perivascular lymphocytic infiltration 884, 885, 887
prevention 891
T lymphocyte responses 887–888
treatment 889–891

human antivaricella zoster immunoglobulin 704
Hu 39694 virus 705
human herpesvirus 1 (HHV1) 607
human enteroviruses (HEV) 607, see human cytomegalovirus
human coronavirus OC43 (HCoV-OC43) 511
cell attachment protein and receptors 517, 518
diagnosis 517
genes 515
gene organization 516
host range 518
isolation and culture 524
multiple sclerosis and 522
receptors 517
see also coronaviruses

human coronavirus HKU1 (HCoV-HKU1) clinical features of infection 520–521
diagnosis 524
genome organization 516
isolation and culture 524
human coronavirus NL63 (HCoV-NL63) 519
clinical features of infection 520–521
croup 521
isolation and culture 524
receptor (ACE2) 518
human coronavirus OC43 (HCoV-OC43) 511
cell attachment protein and receptors 517, 518
diagnosis 524
genes 515
genome organization 516
HE glycoprotein 514
host range 518
isolation and culture 524
multiple sclerosis and 522
proteins 512
see also coronaviruses
human cytomegalovirus see cytomegalovirus (CMV)
human endogenous retroviruses (HERVs) 872
HERV-K 872
HERV-W 872
human enteroviruses (HEV) 607, 607
see also enteroviruses
human herpesvirus 1 (HHV1) see herpes simplex virus 1 (HSV-1)
human herpesvirus 2 (HHV2) see herpes simplex virus 2 (HSV-2)
human herpesvirus 3 (HHV3) 96
see also varicella zoster virus (VZV)
human herpesvirus 4 (HHV4) 96
human herpesvirus 5 (HHV5) 96
see also cytomegalovirus (CMV)
human herpesvirus 6 (HHV-6) 223–244
antibodies 229, 230, 231, 234
detection 236–237
IgG and IgM 236

Subject Index

IgG cross-reaction with HHV-7 IgG 230, 237
antigen detection 237
antiviral therapy 240
CD4+ T cell infection 235
cell tropism 225
chromosomal integration 226, 241
antiviral drug effect 232, 235
clinical consequences 232
diagnosis 237
diagnostic pitfalls due to 239
disease association 231–232
mechanism 227
prevalence 228
reactivation 227–228
site (chromosome 17) 226, 227, 228
transmission from stem cell donors 230
‘chronic active’ infection 232
genital infections 229–230, 232
convulsions and meningoencephalitis 232, 239
copies of DNA/cell 226–227
cytopathic effect 224, 224, 237
disease associations 231–236
encephalitis due to 232, 234–235
after HSCT 236
diagnosis 239
treatment 240
epidemiology and pathogenesis 228–231
gene regulation/expression 224, 226
disease association 231–232
HHV-6A and HHV-6B variations 224–225
genomics 224–225
glycoproteins 225
HHV-6A 96
epidemiology and primary infections 228
genomics 224
strains (Z29 and HST) 224
tissue distribution 228
HHV-6B 96
encephalitis after HSCT 236
disease association 232
HHV-6A and HHV-6B from transplant donors 230
disease association 234–235
genomics 224–225
tissue distribution 228
transmission 229
horizontal 229
nosocomial/iatrogenic 230
perinatal 230
vertical 229–230, 230
from transplant donors 230
in transplant recipients 235–236, 239
1994 gene 224, 227
variants 223

human herpesvirus 7 (HHV-7) 96, 223–244
antibodies 229, 230, 231, 234
IgG and IgM 236
IgG cross-reaction with HHV-6 IgG 230, 237
antigen detection 237
antiviral therapy 240
cell tropism 226
disease association 231–236
encephalitis/encephalopathy 232
disease association 239
epidemiology and pathogenesis 228, 229
genes and gene products 225
regulation 224
genome (dsDNA) 223–224
structure/morphology 223–224, 224
superinfection with HHV-7 effect 226
tegment proteins 230
telomeric-like repeats 227, 232
terminal direct repeats (DRs) 224, 227
tissue distribution 228
transmission 229

rubella differential diagnosis 567
in saliva 228, 229
in salivary glands 226
structure/morphology 223–224, 224
superinfection with HHV-7 effect 226
tegment proteins 230
telomeric-like repeats 227, 232
terminal direct repeats (DRs) 224, 227
tissue distribution 228
transmission 229
horizontal 229
nosocomial/iatrogenic 230
perinatal 230
vertical 229–230, 230
from transplant donors 230
in transplant recipients 235–236, 239
1994 gene 224, 227
variants 223

rubella differential diagnosis 567
in saliva 228, 229
in salivary glands 226
structure/morphology 223–224, 224
superinfection with HHV-7 effect 226
tegment proteins 230
telomeric-like repeats 227, 232
terminal direct repeats (DRs) 224, 227
tissue distribution 228
transmission 229
horizontal 229
nosocomial/iatrogenic 230
perinatal 230
vertical 229–230, 230
from transplant donors 230
in transplant recipients 235–236, 239
1994 gene 224, 227
variants 223

rubella differential diagnosis 567
in saliva 228, 229
in salivary glands 226
structure/morphology 223–224, 224
superinfection with HHV-7 effect 226
tegment proteins 230
telomeric-like repeats 227, 232
terminal direct repeats (DRs) 224, 227
tissue distribution 228
transmission 229
horizontal 229
nosocomial/iatrogenic 230
perinatal 230
vertical 229–230, 230
from transplant donors 230
in transplant recipients 235–236, 239
1994 gene 224, 227
variants 223

rubella differential diagnosis 567
in saliva 228, 229
in salivary glands 226
structure/morphology 223–224, 224
superinfection with HHV-7 effect 226
tegment proteins 230
telomeric-like repeats 227, 232
terminal direct repeats (DRs) 224, 227
tissue distribution 228
transmission 229
horizontal 229
nosocomial/iatrogenic 230
perinatal 230
vertical 229–230, 230
from transplant donors 230
in transplant recipients 235–236, 239
1994 gene 224, 227
variants 223

rubella differential diagnosis 567
in saliva 228, 229
in salivary glands 226
structure/morphology 223–224, 224
superinfection with HHV-7 effect 226
tegment proteins 230
telomeric-like repeats 227, 232
terminal direct repeats (DRs) 224, 227
tissue distribution 228
transmission 229
horizontal 229
nosocomial/iatrogenic 230
perinatal 230
vertical 229–230, 230
from transplant donors 230
in transplant recipients 235–236, 239
1994 gene 224, 227
variants 223

rubella differential diagnosis 567
in saliva 228, 229
in salivary glands 226
structure/morphology 223–224, 224
superinfection with HHV-7 effect 226
tegment proteins 230
telomeric-like repeats 227, 232
terminal direct repeats (DRs) 224, 227
tissue distribution 228
transmission 229
horizontal 229
nosocomial/iatrogenic 230
perinatal 230
vertical 229–230, 230
from transplant donors 230
in transplant recipients 235–236, 239
1994 gene 224, 227
variants 223
Subject Index

nucleic acid detection 237, 238
older children/adults 239
PCR 237
latency 226
in organ transplant recipients 236
primary infections
adults 234
antibodies 231, 233
diagnosis 238–239
older children 234, 239
young children 232–234, 238–239
reactivation 234, 235
diagnosis 239
replication 224
rubella differential diagnosis 567
strains (JI and RK) 225
structure/morphology 223–224
transmission 229
horizontal 229
perinatal 230
vertical 230
human herpervirus 8 (HHV8) see Kapossi’s sarcoma-associated herpesvirus (KSHV)
(HHV-8)
human immunodeficiency virus (HIV) see HIV; HIV infection
human metapneumovirus
detection 73
physical characteristics 50
human papillomavirus (HPV)
atypical squamous cells of unknown significance 818
cell/tissue culture 811–812, 817
cross-reactivity of VLPs and virions 811
DNA integration into chromosome 815
E1 and E2 proteins 810, 812, 815
E1 E4 811
E4 protein mRNA 811
E5 protein 810–811
E6 and E7 proteins 810, 815
ever proteins 808, 810, 810
genome 808, 809, 810
genotyping 17
host-coded histone proteins associated 811
HPV-6 813, 814, 815, 826, 819
HPV-8 813, 819
HPV-11 813, 814, 815, 816, 819
replication 811, 812
HPV-16 816, 819
cervical cancer and 814, 815
genome 808, 809, 810
proteins 810, 810, 812
replication 812
HPV-18 816
cervical cancer and 814, 815
HPV-31 811, 812, 816
HTLV-1 interaction 884
in keratinocytes 810, 811
late (L) proteins (L1 and L2) 808, 810, 810, 811
monoclonal antibodies to 811
oncogenicity 813–814
co-factors 814, 815
proteins involved 810
proteins 808, 810, 810–811
replication 810, 811–812
site 811, 812
serology 811, 817–818
transmission 813
sexual 813, 814
types and lesions associated 812, 816–817
virus-like particles (VLPs) 811
see also BK polyomavirus (BKV); JC virus
human papillomavirus (HPV) infection
antibodies 811
cervical cancer 807, 813, 814–815
diagnosis 817–818
hybrid capture method 818
PCR 814, 818
epidermodysplasia verruciformis (EV) 812, 813, 814
genital cancer 813, 814–815
genital infections 813, 814
HPV types and risk 815, 815, 816–817
genital warts 814, 816, 817
high-grade squamous intraepithelial lesions (HSILs) 815
intraepithelial neoplasia 815
low-grade squamous intraepithelial lesions (LSILs) 815
natural history 812–813
pathogenesis 813–817
penile cancer 815
persistent infections 815, 817
in pregnancy 817
premalignant disease (genital) 814–815
in pregnancy 817
primary infections
in organ transplant recipients 236
latency 236
infection process and binding 412–413
outbreaks 421, 427, 422, 423
syncytium formation 413
HPV1 409, 410, 414
interferon response blocking 420
outbreaks 421, 427, 422, 423
pathogenesis 417, 418
replication 416
shedding 417
HPV13 409, 410, 415
airway hyperresponsiveness 418
HN protein structure 413, 413
HPV1 discrimination 426–427
immune response 418, 419
infection process and binding 412–413
interferon I induced by 420
interferon response blocking 420
MHC class I/II induction 419, 420
outbreaks 421, 422, 422, 423
pathogenesis 417, 418
replication 414–415
shedding 417
syncytium formation 413
vaccine (cGp5) 428
HPV4 409, 410, 421
outbreaks 421, 422, 422
HPV5 410
immune evasion 409
interferon response interference 409, 419–420
life cycle 411, 412
M-F bicistronic transcripts 416
monoclonal antibodies to 418, 425
neuraminidase activity 412–413, 414
inhibitors 429
nosocomial spread 424
N-P complex 414, 416
P protein 410–411
proteins 410, 415
receptors 411–414
release of new virions 412, 413
replication 414–416, 415, 420
ribonucleoprotein and nucleocapsids 411, 414
RNA editing 415–416
RNA polymerase complex 414, 416
shedding 417, 419
structure and properties 413, 417
taxonomy 409–410, 410
transcription process 414–415, 415
transmission 416–417, 420–421
types 409
viral interference 414
V protein 416, 420
see also parainfluenza viruses
human parainfluenza virus (HPIV) infections
adult 424
antibodies 425, 426
haemagglutination inhibition 418, 419, 426
monoclonal 418, 425
human parainfluenza virus (HPIV) infections (contd.)
neutralizing 418, 419, 426
children 418, 420
clinical features 417, 421, 423–425
complications 424–425
croup 421, 422–423, 423
diagnosis/detection 425–427
haemagglutination inhibition 426
immunofluorescence 426, 427
PCR 420, 427
diagnosis/detection methods 425
RT-PCR 427
serology 421, 426–427
specimens 425
whole virus 425
epidemiology 409, 420–423, 424
clinical features 417, 421, 423–425
children 418, 420
treatment 413, 429–430
seasonal infections 422, 424
prevention 428–429
pathogenesis 417–418
nosocomial 424
incubation period 416
lower respiratory tract 420, 421, 423
erythroid cell specificity 424
cell tropism 425
transplant recipients 424
treatment 413, 429–430
upper respiratory tract 420, 423
cytolytic 424
immune response 418–420
immunocompromised patients 424
incubation period 416
human parechoviruses (HPeVs) 601
types 1 and 2, acute diarrhoeal disease 364
human parvovirus(es) 853–867
human parvovirus B19 (B19V) 854–865
in bone marrow 856, 857
cell tropism 857–858
culture 863–864
cytopathic effect 858
discovery 853, 856
treatment and prevention 865
erythroid cell specificity 857
genome (ssDNA) 854–855
growth at 37°C 856
haemopoiesis 856, 857
in pregnancy 58, 862
in bone marrow 856, 857
in bone marrow 856, 857
viraemia 856, 857, 858, 861
virus detection 864–865
vaccines 865
antibodies 856, 858, 863
VP1 and VP2 854–855
human parvovirus B19 (B19V) infection antibodies 856, 858, 859, 863
detection 863–864
IgG 856, 857, 858, 864
IgM 856, 857, 858, 861, 862, 864
aplastic crisis 57, 861–862
Subject Index

immune reconstitution inflammatory syndrome (IRIS) 841, 916
immune response 5, 5
immune system 83–85
adaptive 83–84
innate 83
see also antibodies; B lymphocytes; T lymphocytes
immunity
active 85
artificially-induced 85
cell-mediated see cell-mediated immunity (CMI)
humoral 84
mathematical modelling, vaccination 89
natural 84
passive 85
‘sterilizing’ 84, 112
immunoassays
antibody detection 5–6
solid-phase 5, 6
antibody detection 5–6
‘sterilizing’ 84, 112
immunoblot (western blot) see Western blotting
immunochromatography 5, 478
immunocompromised patients
adenovirus infections 475–477
CMV infection see cytomegalovirus (CMV) infection
diagnostic tests 22–23
EBV infection 209, 215–218
herpes zoster 146–147, 153
HHV-6 infection 235–236
HHV-6 infections 235
JC virus (JCV) infection 835
measles complications 544
measles vaccination 554
parvovirus B19 infections 57, 862–863
progressive multifocal leukoencephalopathy 835
rhinovirus infections 497
RSV infection 449
rubella vaccine contraindication 581
varicella (chickenpox) 144, 152
immunodeficiency
HSV infections 102–103
rubella vaccine contraindication 581
immunoelectrode microscopy, subacute sclerosing panencephalitis (SSPE) 549
immunofluorescence (IF) 2
anticomplement (ACIF), CMV 179
viral antigen detection 3–4, 4
immunofluorescence (IF) assay–late antigen (IFALA) assay, CMV 179
immunoglobulin 83
immunoglobulin G (IgG) detection methods 6
see also individual infections
immunoglobulin M (IgM) detection methods 6
persistance 6, 7
see also individual infections
immunoglobulin M (IgM) capture techniques
dengue haemorrhagic fever 683
ELISA see MAC-ELISA
tosavirus 616
mumps 597
Ross River virus 654
rubella vaccine contraindication 581
yellow fever virus 677
immunological memory 84
immunomodulation
by HHV-6 and HHV-7 235, 235, 240
by HSV 102
immunomodulator therapy
coronavirus infections 526
influenza 399
immunoreceptor tyrosine-based activation motifs (ITAMs), EBV latent membrane proteins 203
immunosenescence, CMV associated 175
immunostaining methods 3
immunosuppression
by arenaviruses (LCMV, Lassa virus) 742, 743–744
effect on JC virus infection 837, 839
emerging infections and 71–72
by rabies virus 785
immunotherapy
adoptive, adenovirus infections 482
coronavirus infections 526
hepatitis B 305–306
passive T-cell, CMV 185
indinavir (IDV), HIV infection 927
indirect immunofluorescence, antibodies in
HHV-6/HHV-7 infections 236
infants
CMV infection 171, 174
HHV6 infections 232
RSV infection 444, 446–447, 448, 449, 454
rubella 576, 579
varicella (chickenpox) 142
infection staging, by molecular techniques 16–17
infectious bronchitis virus (IBV) 511, 512
infectious mononucleosis (IM)
CMV causing 174
EBV causing 199, 205–211
children and elderly 209
clinical features 208–209
complications 209–210
diagnosis and laboratory findings 210–211
histology 208, 208
immune response 207–208
immunocompromised 209
incidence/epidemiology 205
pathogenesis 206–207
pregnancy 209
transmission 206
treatment 211
serological testing 22
Influenza (interferon alpha 1), hepatitis C 315
inflammation, HPIV infections 417
inflammatory bowel disease, MMR vaccine and 581
inflammatory mediators, myelin cross-reaction 522
inflammatory reaction
HAM pathogenesis 889
measles 545–546
influenza 373–408
animal models 386–388
antibodies 395, 396
cross-reactive (strains) 383
IgA 402
IgM 395
atypical 21, 22
clinical features 388–391
complications 389–391
diagnosis 391–396
complement fixation 395
haemagglutination 392, 393
haemagglutination inhibition 393, 393, 395–396
immunofluorescence 392, 393
immunological 395–396
nucleic acid techniques 394–395
PCR 394
serological 21, 22, 395–396
subtype-specific 393, 394
virus recognition 392, 393
virus shedding 393–395
double infections 382
encephalitis 387
epidemics 373, 374, 380, 383
H5N1 see under influenza A virus
innate response 400
innate 395
incubation period 52
mixed infections 391
mortality 58, 59
myositis and myoglobinuria 390
nosocomial infections 58–60
management 60
otitis media 390
pandemics 71, 373, 380, 380–381
1918 380, 386
definition 381
H5N1 383
HA subtypes by year 383
origin, antigenic shift and 382–383
Spanish influenza 380–381, 382
vaccine development 404
pathogenesis 383, 385–386
pathology 386, 389
pneumonia 380–390, 396
pregnancy 390–391
prevention 399–404
prophylactic drugs 398
Reye’s syndrome 390, 396
RSV infection vs 450
seasonal 391
clinical features 388, 388–389
spread/transmission see influenza virus
surveillance by GISN and WHO 373, 383
tracheobronchitis and bronchitis 386, 389
treatment 60, 396–399, 397
amantadine, rimantadine 396–398
neuraminidase inhibitors 396, 398–399
resistance 398, 399, 400
ribavirin 396, 398
types/subtype circulation 381
uncomplicated 386, 388
vaccination
access to, improving 60
influenza (contd.)
children and HCWs 59, 404
HCWs, uptake rates 59–60, 404
in pregnancy 391
vaccines 399–404
adjuvants 402
antigenic shift effect on response 401, 402
development 399, 402–403
efficacy/safety 60, 404
inactivated killed-virus 399, 400–402
intranasal 403
live attenuated 399, 402
production schedule 403, 405
recombinant 402–403
recommendations 403–404
requirements 400, 401
split-virus 401, 403
subunit-virus 401, 401–402, 403
whole-virus (killed) 401, 401
viraemia 386
zoonotic infections 386, 387, 391
influenza A virus 374
antigenic shift in HA 381–382, 387
classification 373–374, 384
conserved proteins, diagnosis by 393, 394
culture 392–393, 394, 399
detection see influenza, diagnosis
discovery 373
drug resistance 398, 399, 400
genome (RNA) 374
glycoproteins 374
growth in cell lines 378
haemadsorption 392
haemagglutination inhibition (HI) 393, 393–395
haemagglutinin (HA) 374, 384
antibodies 400
antigenic shift 382, 382–383
cleavage sites and mechanism 386–387
functions 374, 386
H5 and H7 subtypes 386
HA1 and HA2 374, 378, 386, 392
subtype cross-reactivity 382, 400
subtype distribution 376
virus binding role 378
host range 376–377
immune evasion 380
infection route/process 385, 385–386
infections dose 59
interferon antagonism 380
M1 (matrix protein) 374
M2 374, 378, 398
mRNA transcription/synthesis 378–379
cap snatching 379
mutation 70
neuraminidase (NA) 374–375, 384
3D structure 398
antibodies 400
antigenic differences 384
function 375, 386
inhibitor resistance 399, 400
inhibitors 397, 398–399
subtype classification (N1–N9) 375
subtype distribution 376
nomenclature 384, 384
nonstructural proteins (NS1 and NS2) 376, 380
nucleocapsid/nucleoprotein 374
PB1, PB2 and PA proteins 375, 379
PB1-F2 protein 376
permissive infection 377–378
persistence in environment 49, 59
physical characteristics 50
reassortant 71, 382, 402
in amniotic fluid 392
Ann Arbor vaccine strains 402
antigenic diversity 58–59, 380–384
antigenic drift 70, 385, 383–384, 394, 401
antigenic shift 381–383, 402
haemagglutinin (HA) 382, 382–383
antigenic variants 376
detection 394
antigens 400
assembly 380
attachment 377–378, 386
attenuation methods 402
avian reservoir 74, 376
classification 373–374, 384, 393
conserved proteins, diagnosis by 393, 394
culture 392–393, 394, 399
detection see influenza, diagnosis
discovery 373
drug resistance 398, 399, 400
genome (RNA) 374
glycoproteins 374
growth in cell lines 378
haemadsorption 392
haemagglutination inhibition (HI) 393, 393–395
haemagglutinin (HA) 374, 384
antibodies 400
antigenic shift 382, 382–383
cleavage sites and mechanism 386–387
functions 374, 386
H5 and H7 subtypes 386
HA1 and HA2 374, 378, 386, 392
subtype cross-reactivity 382, 400
subtype distribution 376
virus binding role 378
host range 376–377
immune evasion 380
infection route/process 385, 385–386
infections dose 59
interferon antagonism 380
M1 (matrix protein) 374
M2 374, 378, 398
mRNA transcription/synthesis 378–379
cap snatching 379
mutation 70
neuraminidase (NA) 374–375, 384
3D structure 398
antibodies 400
antigenic differences 384
function 375, 386
inhibitor resistance 399, 400
inhibitors 397, 398–399
subtype classification (N1–N9) 375
subtype distribution 376
nomenclature 384, 384
nonstructural proteins (NS1 and NS2) 376, 380
nucleocapsid/nucleoprotein 374
PB1, PB2 and PA proteins 375, 379
PB1-F2 protein 376
permissive infection 377–378
persistence in environment 49, 59
physical characteristics 50
reassortant 71, 382, 402
receptor binding 377–378, 386
replication 377, 378, 378–380
RNA polymerase 375, 378–379
shedding 59, 389, 392
detection 393–395
sites 393
time course 392, 392
stilet acid receptors 378, 379, 386
structure/morphology 373–374, 375
subtypes 376, 382, 383, 384, 384, 393
diagnosis 393, 394
swine 384
transmission 52, 59, 385–386, 388
aerosols 59
airborne 59
rates in hospitals 58
vaccines see under influenza
variation 380–384
virion RNA (vRNA) synthesis 379–380
virulence determinants 386–387
Von Magnus phenomenon 377
zoanotic infections 386, 387, 392
Influenzavirus 373
Inkoo virus 702, 709
innate immune system 83
in situ hybridization, HSV 107
insulin-dependent diabetes mellitus (IDDM),
congenital rubella syndrome 575
insulin receptor substrate 1 (IRS-1) 842
’intent to harm’ 69
see also bioterrorism
interferon 83
classification/types 299
HPV infection treatment 819
inhibition/interference
adenoviruses 470
HSV infection 102
KSHV 261
pegylated (PEG-IFN) 300
coronavirus infections and SARS 526
hepatitis B 300
hepatitis C 314
hepatitis D 309
side effects 315
type I 419
type II 419
interferon-α
adult T-cell leukaemia treatment 890
CMV infection prophylaxis 186, 187–188
contraindications 299
coronavirus infections and SARS 526
treatment 611
HAM treatment 890
hepatitis B 297, 299–300
hepatitis C 312, 314–315
LCMV infections 742, 743
PML treatment 847
in rabies 785
rhinovirus infection treatment 500, 501
side effects 299–300, 315
interferon-α2a, pegylated, hepatitis C 314
interferon-α2b, pegylated, hepatitis C 314
interferon-βD, coronavirus infection
treatment 526
Subject Index

995

interferon-β 299
hepatitis C 315
impaired production, rhinovirus
infections 496
interferon-γ 299
impaired production, rhinovirus
infections 496
interferon regulatory factors (IRF), KSHV
homologues 253, 257, 260
interferon-stimulated response elements (ISREs),
KSHV infection 260
interleukin-1 (IL-1), IL-2R
interleukin-6 (IL-6), KSHV
intravenous immunoglobulin
intravenous drugs, KSHV transmission 251
intrauterine death (IUD)
intrathecal antibodies, virus-specific 7
intracytoplasmic inclusion bodies 339
Internet, vaccination (mis)information 89, 90
internal ribosomal entry site (IRES)
interleukin-12 (IL-12), hepatitis B therapy 305
interleukin-8 (IL-8)
intravenous immunoglobulin (IVIG)
irradiation 103
Ippy virus 734
islet cell antibodies 575, 613
isolation procedures, Lassa fever 750
isotubine, hepatitis C treatment 316
Issyk-Kul virus 703, 726
Itaqui virus 702, 710
Ixodes, tick-borne encephalitis virus
transmission 692

J
Jamestown Canyon virus 702, 709
Japanese encephalitis 684–687
clinical/pathological features 685–686
control 686–687
diagnosis 686
IgM 686

immunization 686
incubation period 686
vaccines 686
vector control 686–687
Japanese encephalitis virus (JEV) 669, 673,
684–687
characteristics and host range 685
distribution and vector 675
genotypes 685
isolation 686
Nakayima-NIH strain 686
neurotropism 685–686
non-neuroviral mutant 685
prM and E proteins/gene 685
SA14 strain 686
target cells (T cells) 685
Japanese fulminant hepatitis (JFH-1) 310
jaundice 275
JC virus (JCV) and JCV infection 823
activation 836–838, 840, 846
aggnogene/aggnprotien 825–826, 842
antibodies/humoral response 834, 845, 846
apoptosis interference 825, 841
archetype virus and rearrangements (TCR
types) 832–833
assembly and release 826
in astrocytes 841
asymptomatic infections 836–838
BAG-1 interaction 830
BKV co-infection 836
cell signalling disruption 842
cell targets 835–836
see also normal human immunoglobulin
(NHG)
intravenous drugs, KSHV transmission 251
intravenous immunoglobulin
adenovirus infections 482
see also normal human immunoglobulin
(NHG)
intrususception, rotavirus vaccine use and 344,
345
Ippy virus 734
iridocyclitis, HSV 118, 119
Ikut virus 779
iron, serum levels, Japanese encephalitis 686
ISCOMS 402
Isla Vista virus 704
islet cell antibodies 575, 613
isolation procedures, Lassa fever 750
isotubine, hepatitis C treatment 316
Issyk-Kul virus 703, 726
Itaqui virus 702, 710

haematogenous spread 835
HHV-6 co-infection 831
HIV-1 co-infection 831, 837, 841, 844, 914
IgG 846
IgM 834, 846
immune response 845–847
immunosuppression effect 837, 839
large T antigen (TAg) 825, 826, 830, 831,
842
apoptotic function 826
pRB and p53 interference 842
life cycle 825–826
lymphocytes as reservoir 835
lytic control element (LCE) 830
minimal core promoter (MCP) 830
NF-1-binding site (NF-1A/B) 830, 836
NFAT1 binding 828
NFkβ binding 828
NFkβ/Rel action 830
necroinfections regions 830, 832
oncogenicity 841–843
OP-1 motif interaction 830
origin of replication (ORD) 826, 827–828
pathogenesis 835–836
pathology 838, 840
in PBMCs 835, 836, 837
PCR 843–844
persistent infection 834–836, 844
activation 836–838, 840, 846
sites 835
pregnancy 837
primary infections 833–834
promoters 828, 830, 831, 832
proteins 828
pur a interaction 830
receptor and attachment 824, 836
replication 825, 836
inhibitors 847
shedding/virus, 837, 844
small t antigen (Ag) 826, 842
SP1-binding sites 830
spread to CNS 835
structure 823, 824
T’135, T’136, T’165 proteins 826
TATA box and 827, 832
SP1-binding sites 830

T135, T136, T165 proteins 826

Tst-1 functions 830
Tst-1/SCIP/Oct-6 830
Tst-1/SCIP/Oct-6 830

Tst-1/SCIP/Oct-6 830

transcriptional expression 882–830
transcriptional factors and 830
transmission 833–834
treatment of infections 847–848
Tst-1 functions 830
Tst-1/SCIP/Oct-6 830

Tst-1/SCIP/Oct-6 830

neurosarcoma 843–844
neurosarcoma 843–844
viraemia and virus load 837
viraemia and virus load 837

viraemia and virus load 837

viraemia and virus load 837

viraemia and virus load 837

viraemia and virus load 837

viraemia and virus load 837

viraemia and virus load 837

viraemia and virus load 837

viraemia and virus load 837

viraemia and virus load 837

viraemia and virus load 837

viraemia and virus load 837

viraemia and virus load 837

viraemia and virus load 837

viraemia and virus load 837

viraemia and virus load 837

viraemia and virus load 837

viraemia and virus load 837
Kaposi’s sarcoma 245
Jenner, Edward 81, 85, 89-90, 634
Jesty, Benjamin 81
joint involvement
human parvovirus B19 (B19V) infection 860-861
rubella 566-567
rubella vaccine response 567, 581
Sinbis virus infection 649
smallpox 629
see also arthralgia
Junin virus 734
detection 745-746
pathology of infection 744
vaccine 747, 750
XIC13 strain 747
see also Argentine haemorrhagic fever (AHF)
Juquitiba virus 704
K
Kaposi’s sarcoma 245
Kaposin 260
Kaposi’s sarcoma-associated herpesvirus (KSHV) (HHV-8) 96, 245-272
angiomagenesis 258-259, 263
antigens 247, 249, 252
detection 261-262
antiviral therapy 263
apoptosis inhibition 256, 259-260
attachment/infection (cell entry) 255-256
B-cell proliferation 258-259
in blood donors 247-248
CDKs/cyc complex 258, 259
C/EBPα and 257
cell culture 254-255, 256
cell cycle regulation 258
clades A-E (K1 variants) 246
clinical features of infections 251-254
primary effusion lymphoma 252-253
see also Kaposi’s sarcoma
diagnostic assays 261-263
discovery 245
DNA-damage response, regulation 258
DNA polymerase genes (viral) 245-246
EBV and HVS homology 245
EBV co-infection 252
genes 249
expression in latency 249, 257
lytic 249
recombinant construction between genomes 246
Subject Index
genome 249, 254
organization 249
variation of isolates 246
global distribution 247-248
glycoproteins 247
G-protein-coupled receptor (vGCR) 258-259
HIV-1 infection and 250, 252, 254, 915, 916
viral load 262
immune evasion 259-260, 260-261
immunofluorescence 261-262, 262
interferon, interference with 261
interferon regulatory factors homologues (vIRFs) 253, 257, 260
vIRF-1 261
vIRF-2 261
vIRF-3 253
K1 gene variants 246
K3 protein (MIR 1) 261
K5 protein (MIR 2) 261
K7 protein 259
K8 protein 253
K9, K10, K11 proteins 253
K10.5 protein 253, 257
KCP (complement control protein) 260
LANA (latency-associated nuclear antigen) 247, 253, 257
antibodies 248
LANA-1 257, 258
LANA-2 253, 257, 260
latency 252-253, 263
genes expressed during 249, 257
proteins 249, 257
replication during 256-257
switch to lytic cycle 257
latent genes 252
long unique region (LUR) of genome 254
lytic proteins 253, 257
lytic replication 252, 254
activation 257
modulator of immune recognition (MIR) proteins 261
molecular biology assays 262-263
M type 246
NF-κB activation 259
orf2 259
orf4 and orf4.1 259, 261
orf5 247
orf73 257
orfK1 260
orfK6 259
orfK8 (K-bZIP) 257
orfK9 260
orfK10.1 253, 260
orfK11.1 260
orfK15 260
orfK74 260
origin and evolution 245-247, 248
p53-mediated apoptosis inhibition 257
particle-infectivity ratio 255
pathogenesis 254-261
proteins role 253
PCR 262-263
persistent 252-256
efficiency, PEL cell lines 252, 256
inefficient, endothelial/epithelial cells 255
stable, endothelial cells 254
prevalence rates 248
proteins 255
latency 249, 257
lytic 253, 257
role in apoptosis 256
transforming/signalling activity 260-261
P (prototype) type 246
Q type 247
receptors 255-256
related viruses 245-246
replication 252, 254
extrachromosomal episomal 252, 256
latent infection 256-257
representational difference analysis 73
risk factors 250
RTA (immediate-early transactivator) 257
in saliva 250, 255
serology 261-262
structure/morphology 246
terminal membrane proteins (TMPs) 260
terminal repeats on genome 249, 257
transformation by 250-256
transmission 249-251
adults 250
blood/IV drugs/transplants 251
children 249-250
homosexuals 250
sexual 250-251
vertical 250
vBcl-2 259
v-cyc 258
vFLIP/orfK13 252, 253, 257, 259
vIL-6 253, 253, 254
role 258-259
viral load 262
vMIPs I-III (chemokines) 259, 261
Karelian fever 648
Kasokero virus 703, 726
keratinocytes, HPV infection 810, 811
keratitis
herpetic 117–119, 118
post-infectious (metaherpetic) 118
keratoconjunctivitis
epidemic, adenoviruses see epidemic keratoconjunctivitis (EKC)
herpes simplex 117–119, 118, 119
ketamine, rabies management 796
Keystone virus 702, 709
Khabarovsk virus 704, 722
Khuband virus 779
Kasukerov virus 703, 726
kinins, production in common colds 494
‘kissing disease’, CMV infection 167, 168
‘kissing’ probes, PCR 10, 11
KI virus 74
Klüver–Bucy syndrome 789
Kobavirus 364
kobuviruses 601
Kokobera virus 364
Kokobera virus 722
Kumlinge virus 673
Kupffer’s spots 543, 545
Korean haemorrhagic fever 721-722
Kunjin virus 673
Kupfer cells, acute hepatitis 273
Subject Index

kuru 939, 952–953, 960
artelogy and epidemiology 948, 952
clinical features/stages 952, 953
incubation period 949, 952
vCJD similarity 956
Kyasanur Forest disease virus (KFDV) 669, 673, 694–695

L
laboratories, PCR, physical organization 13
laboratory request forms 20
remote requesting 22
La Crosse virus 702, 708
detection/identification 705
lactate dehydrogenase (LDH), TTV 867
Lassa virus
Lassa fever 71, 733, 734–750
lactate dehydrogenase (LDH), TTV
infections 330
Lagos bat virus 778, 779
Laguna Negra virus 704
Lake Victoria marburgvirus (MARV) see Marburg virus
lamivudine (3TC) 923
HAM treatment 890
hepatitis B 301
resistance
HBV 299, 301
HIV (M184V) 918, 921, 923, 924
LANA, in KSHV see Kapozi’s sarcoma-associated herpesvirus (KSHV) (HHV-8)
Langerhans cells, HIV infection 904
laryngeal wart 813, 815
laryngotracheobronchitis, acute see croup
laser evaporation, HPV infection 818–819
Lassa fever 71, 733, 748–750
abortion 749
antibodies 750
cellular immune response 743
clinical features 748–749
containment (isolation)/control 750
diagnosis 741, 749–750
epidemiology 749
hepatic pathology 744
history 748
incubation period 748
mortality 748, 749
nosocomial infections 748, 749, 750
outbreaks 748
pathology 744
pharyngitis 748
in pregnancy 749
prognostic markers 749
reinfections 749
rodent control 750
therapy (immune plasma/ribavirin) 750
Lassa virus 734
antigenic relationships 741
cell culture 749–750
classification 733
immune evasion 743
immunosuppression of cellular immunity 743–744
indirect immunofluorescence 750
natural reservoirs 735
phylegetic relationships 739
structure 736
transmission 749
see also arenaviruses
latent infections 83–84
EBV 200, 252
herpesviruses 96
HSV 95, 96
KSHV 256–257
VZV 133, 141–142, 146
latex agglutination
adenoviruses 478
rubella antibody screening tests 576
VZV 151
Latino virus 734
LB80317, hepatitis B 304
LB80331, hepatitis B 304
LB80380, hepatitis B 304
Lechiguanas virus 704
leukemia
adult T cell see adult T-cell leukemia-lymphoma (ATLL)
leukemia-lymphoma (ATLL)
leukemia-lymphoma virus see leukaemia-lymphoma virus
leukaemia
adult T cell see adult T-cell leukemia-lymphoma (ATLL)
leukemia-lymphoma virus see leukaemia-lymphoma virus
leukemia-lymphoma virus
leukemia-lymphoma (ATLL)
leukemia-lymphoma virus
leukemia-lymphoma virus
leukocytes, lymphocyte receptor (LDR), rhinovirus receptor 491, 493, 501–502
lower motor neuron paralysis, tick-borne encephalitis 693
lower respiratory tract infections
adenoviruses 471, 472, 474
coronaviruses 521
HIV 420, 421, 423
RSV 443, 446–447
see also bronchiolitis; pneumonia
LAMP-RFLP analysis, orthopoxviruses 633–634
L-SIGN 518
LTF adjuvant 403
lumbar puncture
HSV encephalitis 122
neonatal HSV 125
lung hyperinflation, RSV infection 448
lung tumours, polyomaviruses 843
lymphadenopathy
EBV infection 208
HIV-negative angioimmunoblastic 254
monkeypox 630
rubella 566, 581
lymphadenopathy virus see HIV-1
lymph nodes, reactive pattern, EBV infection 740
lymphoblastoid cell line (LCL)
EBV-positive B cell lines 204, 211–212
HIV-6A and HIV-6B replication 225
HHV-7 infection (Sup-T1 line) 226
HSB-2 225
Lymphocryptovirus
lymphocyte blastogenic response, CMV infection 171
lymphocytes, arenavirus replication in 742
lymphocytic choriomeningitis (in humans) 733, 744–745
cellular features 744–745
epidemiology 745
pathology 744–745
lymphocytic choriomeningitis virus
(LCMV) 733, 734
antibodies 742, 743
antigenic determinants 743
antigenic relationships 741
Armstrong strain 743
classification 733
cytotoxic T cells (CD8+) 742, 743–744
genoine 738, 740
geographical distribution 735
human infections see lymphocytic choriomeningitis
immune response 741–742
interferon-α 742, 743
monoclonal antibodies to 737
natural reservoir 733
pathogenesis (in mice) 742
persistence (in mice) 742, 743–744
phylogenetic relationships 739
T cell immunosuppression/‘tolerance’ 742, 743–744
transmission 745
variant in primates 745
see also arenaviruses
Machupo virus  702, 707

MAC-ELISA  734

M-6-P knockdown MeWo cell line, VZV  206

magnetic resonance imaging (MRI)  185

Malignant lymphoma  216

major histocompatibility complex (MHC)  201–202

measles  533–539

acute clinical features  542–543

pathogenesis  545–546

treatment  552

acute post-infectious encephalitis

(AMEP)  544

pathogenesis  548

treatment  552

adenovirus co-infection  473

antibodies  547, 550, 551, 553

in infants  45

atypical presentations  44, 543

cellular immunity  545, 547, 553

children  533, 552

clinical course  542

clinical features  542–545

rash  543, 544, 547

complications  543–545

immunocompetent patients  544

immunocompromised patients  544

delayed hypersensitivity reaction  545, 546,

547–548, 553

diagnosis  44–45, 551–552

immunofluorescence and RT-PCR  551

serological  551

virus isolation/detection  551–552

epidemics  533

epidemiology  533, 541–542, 554

serological  551

virus isolation/detection  551–552

infection  533

in hospitals  44–45

immunity  533, 541, 552

in HCWs  45

incubation period  52, 543

lymphopenia  545

management  552

mortality  44, 533, 554

nosocomial infections  44–45

pathogenesis  545–551, 546

pneumonia  543, 544, 552

pre-exposure vaccination  45

prevention  552–555

re-emergence  44

resurgence, causes  554–555

rubella differential diagnosis  567

secondary viremia  543, 545

SSPE see subacute sclerosing panencephalitis (SSPE)

vaccination  552–555

contraindications (pregnancy)  554

coverage  554

HIV-infected patients  554

immune response to  553

immunocompromised patients  554

incomplete  543

intestinal bowel disease and  553

low uptake rates  552

lymphocytosis

EBV infection  208

lymphocytic choriomeningitis  745

lymphoepithelioma  214

lymphoma

adult T-cell see adult T-cell

leukemia-lymphoma (ATLL)

B-cell see B-cell lymphoma

body cavity-associated (BCCL)

lymphoma, primary effusion (PEL)

Burkitt’s see Burkitt’s lymphoma (BL)

cutaneous T-cell  875

diffuse large-cell (B-cell)  216

EBV association  199, 205, 206, 216, 916

pathogenic mechanism  201–202

HHV-6 association  231

in HIV infection  915–916

Hodgkin’s see Hodgkin’s disease (HD)

large-cell immunoblastic  252

lymphocytic, Burkitt’s  212

non-Hodgkin’s see non-Hodgkin’s

lymphomas

primary CNS  217

in HIV infection  915–916

primary effusion (PEL)  206, 245

clinical features  252–253

HIV infection  915, 916

lymphopenia, measles  545, 547, 553

‘lyssa bodies’  796

Lysavirus  778, 779

genotype 1 see rabies virus

genotype 2 (Lagos bat virus)  778, 779

genotype 3 see Mokola virus

genotype 4 (Duvenhage)  792–793

genotype 5 see European bat lysavirus (EBLV), EBLV-1

genotype 6 (EBLV-2)  782, 783, 793

genotype 7 see Australian bat lyssavirus (ABLV)

hosts  778

phylogroups  778, 779

lyssavirus infections  777–806

see also rabies
monkeypox (contd.)
rodent reservoir 72
smallpox relationship 630
treatment 635
monkeypox virus 625, 630
host, distribution 626
phylogeny 626
transmission 630
monkeys
filovirus infections 755–756, 756–761, 763, 767–768
see also primates
monocytes
EBV infection 204
rhinovirus infection 495–496
Mononegavirales 373, 409, 441, 535, 766
Monogonchela virus 704
mononuclear cells, atypical, EBV infection 208, 209, 210
Monospecies test 210–211
Mopelia virus 734, 736, 739
antigenic relationships 741
Morbillivirus 410, 410, 535
viruses included 535
mortality, infectious diseases, USA 69, 70
mosquito-borne viruses
bunyaviruses 701
control strategies 677, 678, 684, 686–687
flaviviruses 672, 673
dengue 680–681
yellow fever 674, 675
Rift Valley fever virus 712–713
see also specific mosquito genera
Motavirus, RSV infection prevention 454
mouse L cells, arenavirus culture 739
Motavizumab, RSV infection prevention 454
mouse L cells, arenavirus culture 739
mumps 593–600
antibodies 594, 595
assays 597
IgM 597
arthralgia/joint involvement 597
children 598
clinical features 595–597
community outbreaks 46
complications 596–597
endocardial fibroelastosis 597
epidemiology 598–599
hearing defect 597
history 593
hospital outbreaks 46
immunity 598
incubation period 52, 595
interferon role 595
laboratory diagnosis 597–598
antibody assays 597
virus detection 597–598
meningitis and encephalitis 595, 596–597
military personnel 593, 597
myocarditis 597
nosocomial infection 45–46
oophoritis 597, 598
orchitis 597, 598
pancreatitis 597
parotitis 595–596, 596
pathogenesis 595, 595
pathology 595
pregnancy 597
prevalence reduction by vaccination 63
reinfections 598
required vaccination coverage 82
seasonal variations 598
secondary virae mia 595
transmission route 46
vaccination 598–599
infection incidence reduction 46
problems eliminated by
meningitis risk 596–599
status affecting clinical features 596
virus strains 598–599
mumps virus 593–594
antigenic structure 594
classification 593
excretion/shedding 595, 596
F protein (F0, F1, F2) 594
genetic variation between strains 594
genome (negative-sense RNA) 593
genomic organization 594
growth in cell culture 595, 597
HN glycoproteins 593–594
inflammatory mediator cross-reaction 522
myelitis, herpes zoster complication 147
myelopathy
HTLV-1 associated see HTLV-associated myelopathy/tropical spastic paraparesis (HAM-TSP)
HTLV-2 886
myelosuppression, CMV causing 175
myocarditis
adenovirus infections 477
coxackievirus group B (CVB) 609, 610–611
enterovirus infections 610–611, 612
mumps 597
neonatal enteroviral 611
myoclonic jerks, SSPE 544, 545
myelitis, herpes zoster complication 147
myopathy
chronic inflammatory, enteroviruses
causing 612
idiopathic inflammatory, TTV infection and 330
myositis, influenza 390
myoglobinuria, influenza 390
myopathy
chronic inflammatory, enteroviruses
causing 612
idiopathic inflammatory, TTV infection and 330
Nairobi sheep disease virus 700–701
Nairovirus 699, 717–721
biochemical properties 700
members and vectors 703
Nanoviridae 325
nasopharyngeal carcinoma (NPC), EBV and 199, 206, 213–215
clinical features 214
diagnosis 214, 215
seroepidemiology and pathogenesis 213–214
treatment and prevention 214–215

Subject Index

structure and physical properties 593, 594
transmission 52, 595
Urabe strain 598
vaccine strains 598–599
V antigen 594
murine hepatitis coronavirus (MHV) 512, 515, 517, 522
receptors 517, 518
murine leukaemia virus (MuLV) 872
murine noroviruses 359
murine PIV1 (MPIV1) 410
Murray Valley encephalitis virus 690–691
Murray Valley encephalitis virus 673, 690–691
Murutucu virus 702, 710
muscle fasciculation, rabies 790
mutation, of viruses 70–71
myalgic encephalomyelitis see chronic fatigue syndrome
Mycobacterium avium-intracellulare (MAI) complex 912
Mycobacterium tuberculosis, in HIV infection 912
mycosis fungoides, HTLV-1 and 886
myelin
breakdown, acute measles post-infectious encephalitis (AMPE) 548
inflammatory mediator cross-reaction 522
myelin basic protein (MBP) 548
myelitis, herpes zoster complication 147
myelopathy
HTLV-1 associated see HTLV-associated myelopathy/tropical spastic paraparesis (HAM-TSP)

myelopathy/tropical spastic paraparesis (HAM-TSP)
HTLV-2 886
myelosuppression, CMV causing 175
myocarditis
adenovirus infections 477
coxackievirus group B (CVB) 609, 610–611
enterovirus infections 610–611, 612
mumps 597
neonatal enteroviral 611
myoclonic jerks, SSPE 544, 545
myoedema, rabies 790
myoglobinuria, influenza 390
myopathy
chronic inflammatory, enteroviruses
causing 612
idiopathic inflammatory, TTV infection and 330
myositis, influenza 390
myristic acid, enteroviruses 603
myristic acid, enteroviruses 603

N
Nairobi sheep disease virus 703, 721
Nairovirus 699, 717–721
biochemical properties 700
members and vectors 703
Nanoviridae 325
nasopharyngeal carcinoma (NPC), EBV and 199, 206, 213–215
clinical features 214
diagnosis 214, 215
seroepidemiology and pathogenesis 213–214
treatment and prevention 214–215
WHO classification 214
national immunization days (NIDs), polio 618
natural history of viral infections 17
natural killer (NK) cells
arenavirus infections 742
CMV protein interference 171–172, 172
evasion, KSHV infected cells 261
HBV clearance 292
Ndumu virus (NDUV) 644, 646
necrotizing enterocolitis, coronaviruses 522
needlestick injuries 32
HIV infection after 33, 34
negative predictive value 16
Negishi virus 673
nef gene
neutrophils 83
neutrophilia, HPIV infection 418
neutralization tests
natural killer (NK) cells
natural history of viral infections 17
national immunization days (NIDs), polio 618
Ndumu virus (NDUV) 644, 646
negative predictive value 16
Negishi virus 673
needlestick injuries 32
HBV infection after 33, 34
HIV infection after 33, 34
neutralization tests
neuraminidase
neural cell adhesion molecule (NCAM), rabies
neuromuscular junctions, rabies virus
neuronal dysfunction, rabies 783–784
neuronal specific enolase (NSE), sporadic
neuronal proliferation 359
neurotrophin receptor (p75), rabies virus
neutralization tests
dengue 680, 683
enteroviruses 616
neurophilia, HPIV infection 418
neutrophils 83
nevirapine
HIV infection 925–926
post-exposure prophylaxis in HCWs 35
Newcastle disease virus (NDV) 410, 413
new variant Creutzfeldt–Jakob disease (nvCJD) 72, 954
see also variant Creutzfeldt–Jakob disease (vCJD)
New York virus 704
NFAT1 (nuclear factor of activated T cells)
HTLV-1 886, 887
JC virus binding 828
NF-κB activation, KSHV infection 259
HTLV-1 infection pathogenesis 886, 887
JC virus binding 828
rhinovirus infections 494
Ngari virus 702, 706–707
nicotinic acetylcholine receptors, rabies
virus 783
Nidovirales 511
Nipah virus 75–76, 410, 424
non-Hodgkin’s lymphomas (NHL)
in AIDS, EBV and 217
EBV association 206
HHV-6 association 231
in HIV infection 915–916
JC virus association 846
non-nucleoside/nucleotide reverse transcriptase inhibitors (NNRTIs) 921, 924–925
adverse effects 925
mechanism of action 925
metabolism/interactions 922–923
resistance 922, 923–924, 925
K103N and Y181C 925
second-generation 925
normal human immunoglobulin (NHIG)
adenovirus infections 482
hepatitis A prevention 279
parvovirus B19 infection 865
noroviruses (NoVs) 355, 358–363
antibodies 361–362, 362
classification 359
diagnosis 55
diversity, genogroups and evolution 362
epidemiology 356, 361–362
by age 357
gastroenteritis due to
clinical features/course 358, 361
pathogenesis 360
prevention 363
genome (positive sense ssRNA) 359, 360
GII-2 (Snow Mountain) strain 361
host genetic resistance 362
immune response 361
incubation period 54
laboratory diagnosis 360–361
nosocomial infections 54–55
management 55
outbreaks in hospitals 54
persistence in environment 49, 55
physical characteristics 50
proteins, structure/function 361
receptors 362
replication and cell culture 359–360
structure 356, 359
transfection of RNA 359
transmission routes 55, 362
Norwalk virus (NV) 358
genome 359, 360
nosocomial infections/transmission 43–68
adenovirus 61
blood-borne infections see blood-borne viruses (BBVs)
blood-contaminated instruments 32
CCHF virus 718
CJD 953–954
CMV 47–48
coronavirus (CoV) 521
Ebola haemorrhagic fever 760, 763
factors increasing 43
hepatitis C 32
HHV-6 230
HIV infection, prevention 931–932
HPIV 424
HSV 53–54
influenza 58–60
Lassa fever 748, 749, 750
Marburg haemorrhagic fever 756
measles 44–45
mumps 45–46
noroviruses 54–55
organ/tissue transplantation 32
parainfluenza virus 60–61
parvovirus B19 56–58
prevention 43–44
renal haemodialysis 32
respiratory viruses 58–63
risk minimisation strategies 30
rotavirus 56, 345
RSV 62–63, 443–444, 455, 457
rubella 46–47
SARS-CoV 61–62
VZV varicella zoster virus (VZV) 11
ward closures 43, 54, 55, 57
NoV see noroviruses (NoVs)
5’ nucleotide oligoprobes, PCR 10, 11
nucleic acid detection
blood/blood products 31
HSV 106–107
influenza virus 394
nucleic acid sequence-based amplification 13–14
nucleic acid sequencing, automated 20
nucleoside analogues
hepatitis B 300–301, 306
HSV infections 108
JC virus infection 847
nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) 921, 922–924
adverse events 922–923
HAM treatment 890
mechanism of action 922–923
resistance 921, 923–924, 924
M184V mutation see lamivudine
Q151M mutation 924
nuttin 3a 261
Nyando virus 702, 708
O
obesity, adenovirus infections associated 477
Ockelbo disease 648, 649
Subject Index

see also cowpox; monkeypox; smallpox

HPV infection 429–430
influenza 60, 398
HSN1 399
structure 397
Ossa virus 702, 710
osteitis deformans, measles virus associated 545
osteomyelitis, in smallpox 629
otitis media
acute, rhinovirus infection
complication 497–498
with effusion (OME)
coronavirus infection 520
rhinovirus infection 497
influenza 390
RSV infection 448
otosclerosis, measles virus associated 545
outcome of viral infections, host factors affecting 1
‘owl’s eye’ intranuclear inclusions 161, 176–177
oxygen, supplemental
RSV infection 452
SARS prevention recommendations 62

vaccination 819–820
virus-like particles (VLPs) 811
see also human papillomavirus (HPV)

Papovaviridae 807, 823
papovaviruses

persistence in environment 49
see also human polyomaviruses;
papillomaviruses

pappataci fever 711
parainfluenza viruses 409–439
animal infections 417
animal viruses 409–410
antigenicity and immunity 418–420
cell culture and tissue tropism 416
chemokines and cytokines 417
detection 425–427

infections
incubation period 52, 416
inflammation due to 417, 418
mortality 60
nosocomial 60–61
pathogenesis 417–418
prevention 428–429
seasonal outbreaks 60
see also human parainfluenza virus(es)
(HPIVs)

life cycle 411, 412
physical characteristics 50
receptors, attachment and host range 411–414
replication 414–416
shedding 417
structure and properties 410–411, 412
taxonomy 409–410, 410
transmission 52, 60–61, 416–417
paralysis, acute flaccid 609
West Nile fever 690

Paramyxoviridae 409, 410, 441, 593
emerging viruses 76

Paramyxovirinae 409, 410
Paramyxovirus, physical characteristics 50
paramyxoviruses

new/emerging 75–76
replication 415
Paraná virus 734
parapoxvirus, host, distribution 626
parapoxvirus infections 635–636
clinical features 635–636
diagnosis, and control 636
pathogenesis 635
parasympathetic nervous system, rhinovirus
infection pathogenesis 495
parvovirus B19 see human parvovirus B19
(PaV B19)

Paraschizoviridae 853
Paraschizovirinae 853
groups/classification 853, 854
Parvovirus, physical characteristics 50
parvovirus B19 see human parvovirus B19

Occluder binding protein 1 (OCT-1) 98
ocular defects, congenital rubella syndrome (CRS) 572, 573–574, 574, 575
ocular infections see eye infections
oligodendrocytes, in PML 840
Oliveros virus 734, 751
Omsk haemorrhagic fever 694
Omsk haemorrhagic fever virus (OHFV) 669, 673, 694
oncogenesis see cancer, oncogenesis mechanisms

Oncorhynchus 870
o’nyong-nyong virus 652–653
ophthalmitis, mumps 597, 598
ophthalmic herpes zoster 146, 147, 153
optical immunoassays (OIA), RSV infection 451
oral hairy leukoplaikia (OHL)
EBV association 199, 218, 912
HIV infection 912
oral infections
HIV infection 912
HSV see herpes simplex virus (HSV) infection
oral rehydration solution (ORS) 344, 344, 356
Oran virus 373

oral mumps 597, 598
oral poliovirus 629
orf 635–636
host, distribution 626
Orboca virus 702, 710
‘original antigenic sin’ 138, 382
Oropouche virus 702, 709–710
Orthobunyavirus 699, 706–711
members and transmission 702

Orthomyxoviridae 373
Orthomyxovirus, physical characteristics 50

Orthopoxvirus 625, 626
orthopoxviruses 625–635
antibodies and serology 633
antigens 626
A-type inclusions 627
B-type inclusions 632
cell culture 632
genome (dsDNA) 626–627
hosts, distribution and disease 626
immunofluorescence (IF) 633
lateral bodies 625–626, 627
mRNA and transcription 627
PCR 633, 634
phylogenetic relationships 626
replication 626–627, 630, 635
structure/morphology 625–626, 627
orthopoxviruses infections 627–632
clinical features 627–632
diagnosis 632–634
immunodiagnosis 633
laboratory diagnosis and specimens 632
management 634–635
molecular diagnosis 633–634
passive immunization 635
phenotypic diagnosis 632–633
treatment (antivirals) 635
vaccination 634–635

P

p53
adenovirus as vector 482
BK virus oncogenicity 843
inactivation, HTLV-1 infection 886
inhibition, KSHV infection 257
JC virus TAg interference 842
KSHV infection treatment 263
Paget’s disease, measles virus associated 545
pain, zoster-associated see zoster-associated pain (ZAP)
palivizumab, RSV infection 63
prevention 454–455
pancreatitis
acute, coxsackievirus group B 614
mumps 597
P antigens, receptor for B19V 857–858
panurethritis, HSV 118
Papillomavirus 807
papillomaviruses 807–822
cell/tissue culture 811–812
chemical properties 807–810
clinical properties 807–810
classification 807, 808
clinical features of infection 807
diagnosis 817–818
early (E) proteins 808–809
genome (dsDNA) 807–810, 809, 810–811
late (L) proteins 808–809, 811
mRNA transcription 808–809
natural history of infections 812–813
persistent in environment 49
physical characteristics 50, 807–810
proteins 808, 810, 810–911
replication 811–812
serology 811
structure 807, 808
supergroups (A-E) 807, 808
transmission 813
Subject Index

parvoviruses 853–867
acute diarrheal disease 365
animal 853, 862, 865
autonomous 853, 854
emerging/new 74
genomic organization 854–855, 855
human see human parvovirus B19 (B19V)
structure 356
passive T-cell immunotherapy, CMV 185
Pasteur, Louis 81, 777
pathogen-associated molecular patterns (PAMPs) 83, 84
pattern recognition receptors (PRRs) 83, 84, 547
PC (proportion of persons immune) 82
pentosan polyphosphate, CJD 961
‘pentaplex’ assay 12
penile cancer, HPV and 815
perineal infections, tests for 21
pericarditis, enteroviral 616
Pergamino virus
peramivir
‘peptide assay’, HIV 908
pentarhinovirus infections 50
pentose, immune response to 81
pentosephosphate isomerase, CMV 185
Penton, Mitchell 81
Pentostam
pentostatin, MTX therapy 82
pentoxifylline
pentosuria
peptide, influenza A 397
peptide assay
peptide binding, influenza 397
peptide mapping, influenza 397
peptide sequencing, influenza 397
peptide vaccines
peptide vaccines, human papillomavirus (HPV) 818
peptide vaccines, influenza 397
peptide vaccines, hepatitis B 305
peptide vaccines, influenza A 397
peptide vaccines, hepatitis C 328
peptide vaccines, hepatitis D 328
peptide vaccines, hepatitis G 328
peptide vaccines, hepatitis E 328
peptide vaccines, HIV 908
peptide vaccines, human papillomavirus (HPV) 818
peptide vaccines, influenza A 397
peptide vaccines, hepatitis B 305
peptide vaccines, hepatitis C 328
peptide vaccines, hepatitis D 328
peptide vaccines, hepatitis G 328
peptide vaccines, hepatitis E 328
peptide vaccines, HIV 908
peptide vaccines, human papillomavirus (HPV) 818
peptide vaccines, influenza A 397
peptide vaccines, hepatitis B 305
peptide vaccines, hepatitis C 328
peptide vaccines, hepatitis D 328
peptide vaccines, hepatitis G 328
peptide vaccines, hepatitis E 328
peptide vaccines, HIV 908
peptide vaccines, human papillomavirus (HPV) 818
peptide vaccines, influenza A 397
peptide vaccines, hepatitis B 305
peptide vaccines, hepatitis C 328
peptide vaccines, hepatitis D 328
peptide vaccines, hepatitis G 328
peptide vaccines, hepatitis E 328
peptide vaccines, HIV 908
peptide vaccines, human papillomavirus (HPV) 818
peptide vaccines, influenza A 397
peptide vaccines, hepatitis B 305
peptide vaccines, hepatitis C 328
peptide vaccines, hepatitis D 328
peptide vaccines, hepatitis G 328
peptide vaccines, hepatitis E 328
peptide vaccines, HIV 908
peptide vaccines, human papillomavirus (HPV) 818
peptide vaccines, influenza A 397
peptide vaccines, hepatitis B 305
peptide vaccines, hepatitis C 328
peptide vaccines, hepatitis D 328
peptide vaccines, hepatitis G 328
peptide vaccines, hepatitis E 328
peptide vaccines, HIV 908
Subject Index

hepatitis E virus 280–281
HBV origin 897–898
KSHV origin and related viruses 245–246
monkeypox 72
new/emerging viruses 72, 76
rhinovirus infections 493
Rift Valley fever virus 716
rubella virus infection 565
TTV infections 327
as virus vectors 76
primate T-cell lymphotropic virus (PTLV) 876, 883
prion diseases 939–968
acquired 949, 950, 952–957, 960
see also kuru; variant Creutzfeldt-Jakob disease (vCJD)
aetiology and epidemiology 948–949
animal 939, 947
clinical features and diagnosis 949–959, 950
human 939, 948–949
iatrogenic see Creutzfeldt-Jakob disease (CJD)
icubation period 948–949
inherited 949, 950, 957–959
initiation/entry route 947
lesion profiles 943
lymphoreticular tissue 946, 947
molecular diagnosis 959–960
neuronal cell death 945
pathogenesis 946–947
pre-symptomatic/antenatal testing 960
prevention and public health 960–961
PRION I trial 961
prognosis and treatment 961
sporadic 949–952, 950, 959
see also Creutzfeldt-Jakob disease (CJD)
prion protein (PrP) 940
β-sheet state 942
conserved genes 946
copper metabolism role 940, 944
collapsing 940, 941, 942, 942
gene see PRNP
glycosylation 940, 941, 944
gene expression 961
lysosomal delivery role 943
neurotoxicity mechanism 945
normal cellular function 943
octapeptide repeat insertion (OPRI) 957, 959
PrP 6 OPRI 959
PrP7–30 940
PrP102 957
PrP117V 957
PrP 940
apoptosis role 945
conversion to PrPSc 940, 941, 952
destabilization, diseases 941
expression interference 961
minor conformational 941
molecules binding, CJD treatment 961
N/C-terminal regions 940
structure 940–941
PrPD178N 957–958
PrP1200K mutation 958–959
PrP 945
Subject Index

A

duration/progression and outcome 841
HAART effect 840, 841, 847
in HIV infection 840, 841, 844, 914
IgM antibodies 846
immune response in 846
immunocompromised patients 835
JC virus spread to CNS 835
JCV virus 837
pathogenesis/lesion development 840, 841
transcriptional control region (TCR) type 833
treatment 847
promoter-insertion hypothesis 307
Prospect Hill virus 704, 722
protease inhibitors (PI) 921, 925–928
D30N and L90M mutants 920
first-generation 926
HIV infection 903, 917
mechanism of action 925
mutations/resistance 920
new drugs 926
resistance/mutations 926, 926, 927
protective antigens 85–86
protein phosphatase 2A (PP2A) 842
proteinuria, haemorrhagic fever with renal syndrome (HFRS) 724
PrP see prion protein (PrP)
pseudocowpox 635
host, distribution 626
ptosis, herpes zoster 147
pseudocowpox 635

R
rabies 777–806
aerophobia 788
alternative names 777
animals 798
bats 782, 783, 787, 801
clinical features 787
treatment 800–801
diagnosis 795
dogs 777, 782, 783, 787, 796, 801
foxes 781, 782, 801
immune response 785
incubation period 787
raccoons 782, 801
recovery and chronic infection 787, 791–792
treatment 796
vampire bats 783, 787, 790, 801
antibodies 796

Q
quadriaparesis, rabies 790
qualitative detection of viruses 16
quality control, molecular amplification techniques 15, 16
quassiepecies, viral 18, 523
quassiepecies, viral 18, 523
quasi-species, viral 18, 523
quasi-species, viral 18, 523
resistance/mutations 920
neuro-invasion 947
molecular strain typing 944, 946
entry route 947
molecular strain typing 944, 946
entry route 947

P
PrP see prion protein (PrP)
pseudocowpox 635
host, distribution 626
ptosis, herpes zoster 147
pseudocowpox 635
host, distribution 626
ptosis, herpes zoster 147
pseudocowpox 635
host, distribution 626
ptosis, herpes zoster 147
pseudocowpox 635
host, distribution 626
ptosis, herpes zoster 147
pseudocowpox 635
host, distribution 626
ptosis, herpes zoster 147
pseudocowpox 635
host, distribution 626
ptosis, herpes zoster 147
pseudocowpox 635
host, distribution 626
ptosis, herpes zoster 147
rabies (contd.)
- aerosol 786
- bites 798
- human to human 786
- routes 786
- see also rabies, bites
- transplacental 786
- vaccine-induced 786
- vaccines 797–800
- for animals 801
- animal species/behaviour and 798
- antigen stability 781
- booster doses 797–798, 800
- developing countries 800
- duck embryo 791–792
- efficacy against rabies-related viruses 799–800
- eight-site intradermal regimen 800
- exposure confirmation 798
- “failures” 799
- four-site intradermal regimen 800
- historical aspects 777–778
- human diploid cell (HDCV) 778, 797, 800
- immunity response to 785–786
- infection site affecting 798
- Pasteur’s 777, 778
- post-exposure 796, 797, 798–800
- post-exposure, decision to use 798
- post-exposure, efficacy 799
- post-exposure in vaccinated patients 799
- pre-exposure 796, 797–798
- primary post-exposure 799
- purified chick embryo cell (PCEC) 792, 797
- purified Vero cell (PVRV) 792, 797
- recombinant 801
- recovery after 791–792
- regimens 796, 797, 799
- Semple brain tissue 777, 800
- side effects 800
- two-site intradermal regimen 800
- viraemia 784
- wound treatment 799
- rabies-related viruses
- human infections 792–793
- vaccine efficacy 799–800
- see also European bat lyssaviruses (EBLV)
- rabies virus 779
- antigens 784, 785
- detection 794–795
- assembly, maturation and release 781, 785
- attachment and fusion 780, 783–784
- brain infection 784
- centrifugal spread from brain 784–785
- classification 778
- genome (negative-sense ssRNA) 778
- G (glycoprotein) protein 778, 780
- host gene expression downregulated 784
- inactivation 781
- infection routes 786, 798
- intracerebral transport 780
- isolation/identification 794–795
- L protein (RNA polymerase) 778, 780
- M (matrix) protein 778, 780
- N (nucleoprotein) protein 778, 785
- P (phosphoprotein) protein 778, 780, 784
- replication 780–781
- inhibition by interferon-α 785
- sites 784–785
- RNA polymerase 778, 780
- RNP complex 778, 780–781
- shedding 784
- stability 781
- structure 778, 779, 780
- transmission see rabies, transmission transport to brain 784
- vectors/reservoirs 781–783
- raccoons, rabies 782, 801
- raltegravir (RAL) 922, 929
- Ramsay-Hunt syndrome 146
- RANTES 417
- rapamycin, KSHV infection 263
- rapid immunofluorescent focus inhibition test (RIFFIT), rabies 786
- rash(es)
- Barmah Forest virus (BFV) 655
- Chikungunya virus infection 651
- Crimean–Congo haemorrhagic fever 719
- EBV infection 209
- HHF-6 infections 232
- human parvovirus B19 (B19V) 856, 860
- Lassa fever 748
- measles 543, 544, 547
- monkeypox 630
- o’nyong-nyong virus 652
- in pregnancy 21
- rapid immunofluorescent focus inhibition test (RIFFIT), rabies 786
- respiratory rate, RSV infection 447
- respiratory syncytial virus (RSV) 441–461
- adsorption 442
- antigenic variation 442
- classification 441
- cp (cold passage)/ts (temperature sensitive) mutants 453, 454
- cytopathic changes 450–451
- detection see respiratory syncytial virus (RSV) infection, diagnosis discovery 441
- gene variants (polymorphisms) 450
- genome (negative-sense RNA) 441
- glycoproteins (F and G) 441–442
- antibodies to 442, 445, 446
- monoclonal antibody to F 454
- vaccine development 454
- isolation 450–451
- persistence in environment 49, 444, 455
- physical characteristics 50
- replication 442
- shedding 62, 449
- strains A and B 442
- structure/morphology 441, 442
- transmission 52, 62–63, 443–444
- prevention 62
- to/h by HCWs 444
- respiratory syncytial virus (RSV) infection acute complications 448
- antibodies 446
- detection 452
- IgA 445
- IgM and IgG 445, 452
- maternal 445
- neutralizing 442, 445
- bronchiolitis 443, 444–445, 445, 446–447, 453
- children 441, 443, 446–447, 449
- clinical features 446–448
- children at increased risk 449
- older children/adults 450
- primary infection 447–448
- co-infections 448
- cytopathology 446
- diagnosis 63, 450–452
- enzyme immunoassays 451
- immunofluorescence 4, 451, 451
- PCR 451
- serologic 451–452
- elderly 450
- epidemiology 441, 442–444, 447
- of HCWs 444
- immunity to 445–446
- cellular 446
- humoral 445–446
- innate 445, 446
- Th1 and Th2 responses 446, 450
- immunocompromised patients 449
- incubation period 52, 444
- infants 444, 446–447, 448, 449
- immunization 454
- influenza v 450
- management 63, 452–453
- mortality 444
<table>
<thead>
<tr>
<th>Subject Index</th>
<th>1007</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute retinal necrosis</td>
<td></td>
</tr>
<tr>
<td>HSV 118, 126</td>
<td></td>
</tr>
<tr>
<td>VZV 147–148</td>
<td></td>
</tr>
<tr>
<td>progressive outer (PORN) 148</td>
<td></td>
</tr>
<tr>
<td>rapidly progressive herpetic 148</td>
<td></td>
</tr>
<tr>
<td>CMV 190, 912</td>
<td></td>
</tr>
<tr>
<td>varicella (chickenpox) and 145</td>
<td></td>
</tr>
<tr>
<td>RGD motif</td>
<td></td>
</tr>
<tr>
<td>adenoviruses 467</td>
<td></td>
</tr>
<tr>
<td>KSHV glycoprotein 255</td>
<td></td>
</tr>
<tr>
<td>Rhodoviridae 779</td>
<td></td>
</tr>
<tr>
<td>rhesus monkey papillomavirus type 1 814</td>
<td></td>
</tr>
<tr>
<td>Rhesus monkeys, ZEBOV (Ebola Zaire virus) 767</td>
<td></td>
</tr>
<tr>
<td>rhesus rotavirus (RRV) 343</td>
<td></td>
</tr>
<tr>
<td>rhematomatos arthritis, parvovirus B19V role 861</td>
<td></td>
</tr>
<tr>
<td>rhinoviruses 489–510</td>
<td></td>
</tr>
<tr>
<td>2A protease and 3C protease 492</td>
<td></td>
</tr>
<tr>
<td>antigenicity 490–491</td>
<td></td>
</tr>
<tr>
<td>canyon 490, 491</td>
<td></td>
</tr>
<tr>
<td>‘canyon hypothesis’ 491</td>
<td></td>
</tr>
<tr>
<td>capsaid 489–490</td>
<td></td>
</tr>
<tr>
<td>cell culture 498</td>
<td></td>
</tr>
<tr>
<td>cell lines, growth 495</td>
<td></td>
</tr>
<tr>
<td>cytopathic effects 493, 498</td>
<td></td>
</tr>
<tr>
<td>electron microscopy 490</td>
<td></td>
</tr>
<tr>
<td>enteroviruses relationship 489</td>
<td></td>
</tr>
<tr>
<td>genome (positive-sense ssRNA) 489, 491, 492</td>
<td></td>
</tr>
<tr>
<td>groups A and B 489, 496</td>
<td></td>
</tr>
<tr>
<td>history/discovery 489</td>
<td></td>
</tr>
<tr>
<td>murine 871</td>
<td></td>
</tr>
<tr>
<td>pol gene 870</td>
<td></td>
</tr>
<tr>
<td>replication 869–870, 870</td>
<td></td>
</tr>
<tr>
<td>reverse transcriptase 869</td>
<td></td>
</tr>
<tr>
<td>SU protein 870</td>
<td></td>
</tr>
<tr>
<td>taxonomy 870, 872</td>
<td></td>
</tr>
<tr>
<td>TM protein 870</td>
<td></td>
</tr>
<tr>
<td>as vectors for gene therapy 869, 872–873</td>
<td></td>
</tr>
<tr>
<td>zoonotic infections 869, 870–872</td>
<td></td>
</tr>
<tr>
<td>see also HIV; HTLV</td>
<td></td>
</tr>
<tr>
<td>reverse genetics technology</td>
<td></td>
</tr>
<tr>
<td>Ebola virus infections 766, 769</td>
<td></td>
</tr>
<tr>
<td>HPIV vaccine development 428</td>
<td></td>
</tr>
<tr>
<td>influenza vaccine development 399, 403</td>
<td></td>
</tr>
<tr>
<td>measles virus (recombinant) 535</td>
<td></td>
</tr>
<tr>
<td>RSV vaccine development 454</td>
<td></td>
</tr>
<tr>
<td>reverse transcriptase (RT) 869</td>
<td></td>
</tr>
<tr>
<td>discovery 871, 875</td>
<td></td>
</tr>
<tr>
<td>reverse transcriptase nested PCR (RT-nPCR), rubella 577, 578, 580</td>
<td></td>
</tr>
<tr>
<td>reverse transcription PCR (RT-PCR)</td>
<td></td>
</tr>
<tr>
<td>alphaviruses 647</td>
<td></td>
</tr>
<tr>
<td>bunyaviruses 705</td>
<td></td>
</tr>
<tr>
<td>Chikungunya virus 652</td>
<td></td>
</tr>
<tr>
<td>coronaviruses 523, 524</td>
<td></td>
</tr>
<tr>
<td>dengue virus 863</td>
<td></td>
</tr>
<tr>
<td>EIA with (RT-PCR-EIA), HPIV 427</td>
<td></td>
</tr>
<tr>
<td>GBV-C 324, 325</td>
<td></td>
</tr>
<tr>
<td>hantaviruses 726</td>
<td></td>
</tr>
<tr>
<td>HCV infection 311</td>
<td></td>
</tr>
<tr>
<td>HPIV 427</td>
<td></td>
</tr>
<tr>
<td>Lassa virus 750</td>
<td></td>
</tr>
<tr>
<td>measles 551</td>
<td></td>
</tr>
<tr>
<td>noroviruses 55</td>
<td></td>
</tr>
<tr>
<td>rhabies virus 795</td>
<td></td>
</tr>
<tr>
<td>RSV infection 451</td>
<td></td>
</tr>
<tr>
<td>reverse vaccinology 85</td>
<td></td>
</tr>
<tr>
<td>Reye’s syndrome</td>
<td></td>
</tr>
<tr>
<td>HPIV causing 424</td>
<td></td>
</tr>
<tr>
<td>influenza 390, 396</td>
<td></td>
</tr>
<tr>
<td>varicella (chickenpox) and 145</td>
<td></td>
</tr>
<tr>
<td>RGD motif</td>
<td></td>
</tr>
<tr>
<td>adenoviruses 467</td>
<td></td>
</tr>
<tr>
<td>KSHV glycoprotein 255</td>
<td></td>
</tr>
<tr>
<td>Rhodoviridae 779</td>
<td></td>
</tr>
<tr>
<td>rhesus monkey papillomavirus type 1 814</td>
<td></td>
</tr>
<tr>
<td>Rhesus monkeys, ZEBOV (Ebola Zaire virus) 767</td>
<td></td>
</tr>
<tr>
<td>rhesus rotavirus (RRV) 343</td>
<td></td>
</tr>
<tr>
<td>rhematomatos arthritis, parvovirus B19V role 861</td>
<td></td>
</tr>
<tr>
<td>rhinoviruses 489–510</td>
<td></td>
</tr>
<tr>
<td>2A protease and 3C protease 492</td>
<td></td>
</tr>
<tr>
<td>antigenicity 490–491</td>
<td></td>
</tr>
<tr>
<td>canyon 490, 491</td>
<td></td>
</tr>
<tr>
<td>‘canyon hypothesis’ 491</td>
<td></td>
</tr>
<tr>
<td>capsaid 489–490</td>
<td></td>
</tr>
<tr>
<td>cell culture 498</td>
<td></td>
</tr>
<tr>
<td>cell lines, growth 495</td>
<td></td>
</tr>
<tr>
<td>cytopathic effects 493, 498</td>
<td></td>
</tr>
<tr>
<td>electron microscopy 490</td>
<td></td>
</tr>
<tr>
<td>enteroviruses relationship 489</td>
<td></td>
</tr>
<tr>
<td>genome (positive-sense ssRNA) 489, 491, 492</td>
<td></td>
</tr>
<tr>
<td>groups A and B 489, 496</td>
<td></td>
</tr>
<tr>
<td>history/discovery 489</td>
<td></td>
</tr>
<tr>
<td>host range 493</td>
<td></td>
</tr>
<tr>
<td>HRV-2 490</td>
<td></td>
</tr>
<tr>
<td>HRV-14 603</td>
<td></td>
</tr>
<tr>
<td>HRV-87 489, 496</td>
<td></td>
</tr>
<tr>
<td>incubation period 493</td>
<td></td>
</tr>
<tr>
<td>internal ribosome entry site (IRES) 491</td>
<td></td>
</tr>
<tr>
<td>isolation 498–499</td>
<td></td>
</tr>
<tr>
<td>major and minor groups 489, 491</td>
<td></td>
</tr>
<tr>
<td>mRNA 491</td>
<td></td>
</tr>
<tr>
<td>persistence in environment 49, 492, 493</td>
<td></td>
</tr>
<tr>
<td>physical characteristics 50, 492</td>
<td></td>
</tr>
<tr>
<td>‘pocket’ and ‘pocket factor’ 490</td>
<td></td>
</tr>
<tr>
<td>proteins 490, 490</td>
<td></td>
</tr>
<tr>
<td>receptors 491</td>
<td></td>
</tr>
<tr>
<td>replication 491–492, 493</td>
<td></td>
</tr>
<tr>
<td>RNA polymerase 491</td>
<td></td>
</tr>
<tr>
<td>serotypes 496</td>
<td></td>
</tr>
<tr>
<td>shedding 492</td>
<td></td>
</tr>
<tr>
<td>structure 489–492, 490</td>
<td></td>
</tr>
<tr>
<td>taxonomy 489</td>
<td></td>
</tr>
<tr>
<td>transgenic murine model 493</td>
<td></td>
</tr>
<tr>
<td>translation 492–493, 496</td>
<td></td>
</tr>
<tr>
<td>as vectors 491</td>
<td></td>
</tr>
<tr>
<td>VP1-VP4 490, 501</td>
<td></td>
</tr>
<tr>
<td>rhinovirus infections</td>
<td></td>
</tr>
<tr>
<td>antibodies</td>
<td></td>
</tr>
<tr>
<td>IgG and IgA 495</td>
<td></td>
</tr>
<tr>
<td>neutralizing 499</td>
<td></td>
</tr>
<tr>
<td>asthma exacerbation 495, 497–498</td>
<td></td>
</tr>
<tr>
<td>atopy and 496</td>
<td></td>
</tr>
<tr>
<td>bronchitis, bronchiolitis and pneumonia 498</td>
<td></td>
</tr>
<tr>
<td>cellular immunity 495–496</td>
<td></td>
</tr>
<tr>
<td>children 496, 497</td>
<td></td>
</tr>
<tr>
<td>chronic 493</td>
<td></td>
</tr>
<tr>
<td>clinical features 497–498</td>
<td></td>
</tr>
<tr>
<td>498</td>
<td></td>
</tr>
<tr>
<td>cold temperature exposure and 496</td>
<td></td>
</tr>
<tr>
<td>common colds 489, 496–497</td>
<td></td>
</tr>
<tr>
<td>complications 497–498</td>
<td></td>
</tr>
<tr>
<td>in COPD 492, 495, 498</td>
<td></td>
</tr>
<tr>
<td>cytokines/kinins and chemokines produced 494, 495</td>
<td></td>
</tr>
<tr>
<td>diagnosis 498–499</td>
<td></td>
</tr>
<tr>
<td>ELISA 499</td>
<td></td>
</tr>
<tr>
<td>haemagglutination inhibition (HI) 499</td>
<td></td>
</tr>
<tr>
<td>nucleic acid detection 499, 500</td>
<td></td>
</tr>
<tr>
<td>PCR 499, 500</td>
<td></td>
</tr>
<tr>
<td>serology 499</td>
<td></td>
</tr>
<tr>
<td>virus isolation 498–499</td>
<td></td>
</tr>
<tr>
<td>epidemiology 496–497</td>
<td></td>
</tr>
<tr>
<td>immunity/immune response 495–496</td>
<td></td>
</tr>
<tr>
<td>immunocompromised people 497</td>
<td></td>
</tr>
<tr>
<td>incubation period 497</td>
<td></td>
</tr>
<tr>
<td>morbidity 497</td>
<td></td>
</tr>
<tr>
<td>nasal secretions 493–494</td>
<td></td>
</tr>
<tr>
<td>pathogenesis 493–495, 494</td>
<td></td>
</tr>
<tr>
<td>prevention 500–502</td>
<td></td>
</tr>
<tr>
<td>primary site of infection 493</td>
<td></td>
</tr>
<tr>
<td>treatment 494, 500–502, 501</td>
<td></td>
</tr>
<tr>
<td>targets/strategies 492, 494, 495</td>
<td></td>
</tr>
<tr>
<td>vaccine</td>
<td></td>
</tr>
<tr>
<td>decavalent 500</td>
<td></td>
</tr>
<tr>
<td>obstacle to development 500</td>
<td></td>
</tr>
<tr>
<td>viraemia 493</td>
<td></td>
</tr>
</tbody>
</table>
Subject Index

Rocin virus 669, 675, 678–679
rodents

arenaviruses 733, 734, 742
LCMV 741–742, 745
control, Lassa fever control 750
cowpox transmission 631, 632
Ebola (Zaire) virus model 767
filovirus infections 767, 770
hantavirus transmission 73, 75, 721–722, 723
monkeypox reservoir 72
persistent virus infections (arenaviruses) 733, 742
roseola infantum (exanthem subitum) 232
Roseolovirus 224
roseoloviruses 223–244
see also human herpesvirus 6 (HHV-6); human herpesvirus 7 (HHV-7)
Ross River virus (RRV), and infection 644, 648, 653–654
clinical disease 653–654
diagnosis and isolation 654
epidemiology and pathogen 653
pathogenesis 654
rubella differential diagnosis 657
vaccine 654
rotaviruses 337–353
antibodies 338, 342, 343
classification 337–338
double-layered particles (DLPs) 338, 339
classification 337–338
double-layered particles (DLPs) 338, 339, 343
electron microscopy 338, 343, 356
G1-G4 types 345
G9 type 345
G and P types 338, 343–344
gene–protein assignments 340–341
gene–protein assignments 340–341
gene–protein assignments 340–341
 genome (dsRNA) 337, 339
 genic drift 345
 groups A, B, and C 345
 infections in children 343
 clinical features and diagnosis 343–344, 355
 epidemiology 337, 344–345
 immune response and IgA 343
 incubation period 52, 343
 mortality 337, 341
 nosocomial 356, 345
 pathogenesis 342, 342–343
 seasonal 356
 treatment 344, 344
 NSP4 (enterotoxin) 341, 342
 nursery strains 343
 persistence in environment 49, 56
 proteins (VP1-VP3) 337, 339, 340–341
 replication 338–339, 342
 structure 337, 338, 339
 transmission 52, 338
 triple-layered particles (TLPs) 338
 vaccines 56, 85, 345–346
 intussusception cases 344, 345
 lamb strain LLR (live attenuated) 346
 live attenuated 345–346
 monovalent 346
pentavalent 346
tetavalent 345
viromas 339
VP4 and VP7 338, 340, 341
Royal Free disease see chronic fatigue syndrome
RT-PCR see reverse transcription PCR
rubella 561–592
antibodies 561, 565, 568, 569
detection 576–577
loss in congenital rubella 579–580
post-vaccination 580
see also rubella, IgG; rubella, IgM
antibody screening tests 576
clinical features 566
complications 566–567
congenital see congenital rubella syndrome (CRS)
developing countries 566, 585–586, 586
diagnosis/laboratory techniques 576–580
congenitally acquired infection 578–580
enzyme immunoassay (EIA) 576
oral fluid/dried blood spots 577
prenatal 578, 580
serological 576–577, 579
serological in women exposed to RV 577, 578
serological in women with rubella-like illness 577–578
virus detection 577, 579
differential diagnosis 567, 567–568
epidemiology 565–566
fetal infection after reinfection of mother 569
see also congenital rubella syndrome (CRS)
global distribution 564, 565–566
haemagglutination inhibition test 561, 579–580
HCW susceptibility 46
historical events 561, 562
IgA, after vaccination 580
IgG 569, 575, 577, 578
after vaccination 580
avidity 576–577
persistence in infant 579
IgG1, detection 579
IgM 568, 569, 570, 575, 577, 578
after vaccination 580
detection 576, 579
immune response 565, 566, 568–569, 570
immunity 569, 580–581
immunoglobulin (therapeutic) 578
immunosuppression associated 568
incubation period 52, 561
isolation of infants 576
neonatal 570
nosocomial 46–47
pandemics 566
pathogenesis 566
placental infection and 569
post-infectious encephalitis 567
pre-conceptual acquired infection 565–569
pre-conceptual 570–571
ribavirin 314
adenovirus infection 481, 482
Bolivian haemorrhagic fever 747–748
coronavirus infections and SARS 526
Crimean–Congo haemorrhagic fever 720
hepatitis C 314–315
HPV infection 429
influenza 396, 398
Lassa fever 750
measles 552
mechanism of action 398, 452, 482
RSV infection 452
side effects 315, 398, 452, 482, 750
structure 397
riboprobes 14
Rickettsia conorii infection 720
Rift Valley fever virus, and infection 701, 703, 712–717
abortion 716
antibodies 717
clinical features 713, 714, 715–716
detection/identification 705
diagnosis and investigations 716–717
differential diagnosis 717
Egypt epidemics 713–714, 715
encephalitis 715–716
epidemiology 712–714
geographical distribution 712
haemorrhagic form 715
haemostatic derangement 715, 716
infection route 715
Kenya outbreaks 712, 714
mosquito vectors 712–713, 714
ocular disease 715
outbreaks and epidemics 712, 713
pathogenesis of infection 716
pathology 716, 717
Saudi Arabia and Yemen 714
South Africa/Zimbabwe 712
transmission cycles 713
treatment 716
vaccine 717
rimantadine
influenza 60, 396–398
side effects 398
structure 297
Rinderpest virus (RPV) 535
ring sores 635
Rio Bravo virus 672, 673
Rio Mamore virus 704
Rio Segundo virus 704
ritonavir
boosting, protease inhibitors 926
HIV infection 925, 926
rituximab 217
RNA editing, HPV 415–416
RNA interference, filovirus infection therapy 766
RNA replication, HPV vaccine development 429
RNA viruses
nucleic acid sequence-based amplification 13–14
rapid evolution 881
Ro (basic reproductive rate) see basic reproductive rate/number (Ro)
Subject Index

rubella virus (RV)
in pregnancy 46, 561
after first trimester 570
diagnosis/laboratory tests 577–578
first trimester 562, 569, 570
gestational age and 570, 571
management 578
see also congenital rubella syndrome (CRS)
prenatal diagnosis 578, 580
rash 566
reinfection 569, 581
diagnosis 578
risk to fetus 570–571
vaccination 580–586
adverse reactions 581
contraindications 581–582
developing countries 585–586, 586
efficacy and reinfection 581
Europe 584–585
failures 581
immune response 580–581
disease after 567, 581
low/intermediate uptake rates 584, 586
monitoring efficacy, seroprevalence 583
other vaccines with 582
pregnancy 582, 582–583
prevalence reduction by 85, 583, 584, 585
programmes 583–586
required coverage 82
in UK 583–584, 584
in USA 583
WHO recommendations 585, 585–586
vaccines
attenuated, development 580
RA27/3 strain 564, 565, 580
viraemia 568
virological features, clinical feature correlation 568, 568–569
rubella virus (RV)
alphaviruses similarity 562
in amniotic fluid 580
antigenic characteristics 565
assembly and release 564–565
attachment and infection process 564
cell culture 561
clades and genotypes 564
classification 562
C protein 564
in CSF 570
cytopathic effect 565, 577
detection 577
E1 and E2 proteins 562, 564, 565
excretion 569–570, 581
in fetal blood 580
G+C content of RNA 562
genetic variation 562, 564
genome (positive-sense ssRNA) 562, 563
global distribution 564
growth in cell culture 565
interference assay 561
nonstructural proteins 562, 563
origin 71
p150 and p90 564
pathogenicity for animals 565

S
Saaremaa virus 704
Sabá virus 734, 751
sacral ganglia, herpes zoster 146
St Louis encephalitis see St Louis encephalitis (under St)
saliva
CMV in 167, 176
EBV in 206, 215
HHV-6 in 228, 229
HV in, testing 907
KSHV in 250, 255
samples/specimens 20
antibody detection 5
for PCR 9
storage 20
viral antigen detection 4
for 9
salivaria

SARS
SARS-CoV 511
SARS-like coronavirus
in bats 519
in civets 518, 519, 520, 525
SaV see sapoviruses (SaVs)
scaibes, Norwegian, HTLV-1 and 885
SCH 503034, hepatitis C treatment 316
scrapie 939, 947
atypical 947
screening assays 20
'scrum pox' 116
seasonal infections
common colds 496
HPIV infections 422, 422
influenza 388, 388–389, 391
rotaviruses 56
RSV 442, 444
seizures see convulsions
'self' antigens, tolerance 743–744
self-fluorescing amplicon concept, PCR 10, 12
Semliki Forest virus (SFV) 644, 644, 646,
661–662
Semliki Forest virus complex
origins and distribution 650
viruses included 644

elderly 522
emergence 519
epidemiology 519–520
first cases 519
Hong Kong outbreak 61, 62, 71
incubation period 521
mortality 71, 522
nosocomial infections 61–62
prevention/precautions 62
WHO recommendations 62
passive immunization 525–526
pathogenesis and pathology 523
pneumonia 521–522, 526
re-emergence 525
'super-spreading incidents' 519, 520
susceptibility, genetic polymorphisms 523
transmission of virus 519–520
treatment 526
vaccine 525

SARS-associated coronavirus 7, persistence in environment 49
SARS-CoV 511
antigenic structure 517
classification 511
continued circulation, evidence lacking 520
detection/identification 74, 523
genome organization 516
host range and civet SARS-like virus relation 518–519
isolation and culture 524
origin 76–77
persistence in environment 62
receptor (ACE2) 518
re-emergence 61
spike protein, monoclonals to 525–526
transmission 61–62, 519–520
aerosol and droplets 520

SARS-like coronavirus
in bats 519
in civets 518, 519, 520, 525
SaV see sapoviruses (SaVs)
scaibes, Norwegian, HTLV-1 and 885
SCH 503034, hepatitis C treatment 316
scrapie 939, 947
atypical 947
screening assays 20
'scrum pox' 116
seasonal infections
common colds 496
HPIV infections 422, 422
influenza 388, 388–389, 391
rotaviruses 56
RSV 442, 444
seizures see convulsions
'self' antigens, tolerance 743–744
self-fluorescing amplicon concept, PCR 10, 12
Semliki Forest virus (SFV) 644, 644, 646,
661–662
Semliki Forest virus complex
origins and distribution 650
viruses included 644
simian T-lymphotropic viruses (STLV-1, STLV-2) 76, 876, 880
simian T-lymphotropic virus 5 (SIV5) 410, 414
Simplexvirus 95, 96
Simidz-like virus 659
Simidz virus (SINV) 644, 644, 648-649
infection, rubella differential diagnosis 567
cellular radial haemolysis (SRH) technique, influenza 395
Sin Nombre-like viruses 723
Sin Nombre virus 73, 704, 722
see also hantaviruses
SIV/HIV chimaera 931
sixth disease (exanthem subitum) 232
Sjogren’s syndrome 886
skin biopsy, rabies diagnosis 794, 795
skin infections, HSV 116, 127
SLAM (signalling lymphocytic activation molecule) see CD150 (SLAM)
slapped cheek disease (fifth disease) 856, 859-860
’slim’ disease 899
slow virus infection 939
see also prion diseases
small anellovirus (SAV) 326
geno 326, 327
small interfering RNA (siRNA), coronavirus infection treatment 526
smallpox 627-630
animal models and pathogenesis 629
bioterrorism and 629
cause of death 629
classic (ordinary) 628
clinical features and lesions 628-629
diagnosis 632
eradication 81-82, 91, 628
flat-type 628
forms and presentations 628-629
Global Eradication Programme 634
haemorrhagic-type 628
host, distribution 626
immunity 629
incubation period 628
modified-type 628-629
Rao classification 628-629
rash 628
varicella vz 143
sine eruptione 629
transmission 627-628
vaccination 634-635
adverse events and encephalitis 634
cost-effectiveness 91, 91
disclosure, cowpox use 81
mandatory 90
modified vaccinia ankara (MVA) strain 634-635
strains 634
Snow Mountain strain of NoV 361
Snowshoe hare virus 702, 708-709
solid organ transplant recipients see transplantation (organ/tissue) recipients
sporovirus (BVarA), herpes zoster 152-153
’source drying’, concept 89
spasms, rabies 788, 789
specificity of tests 15, 16
specimens see samples/specimens
spindle cells, endothelial cell-derived, KSHV infection 252
splenic rupture, EBV infection 209
Spongweni virus 673
Spumavirinae 870
spumaviruses 871, 872
squamous cell carcinoma (SCC), epidermodysplasia verruciformis and 813
SRSV (small round structure virus) 52
ST-246, vaccinia vaccinatum treatment 635
Staphylococcus aureus methicillin-resistant 23
pneumonia in influenza 390
‘starry sky’ appearance 212, 213
STAT1, interferon response, HPIV infections 419-420
STAT2, interferon response, HPIV infection 420
stem cell transplant patients
HTLV-1 infection treatment 890
screening assays before transplant 20
see also haematopoietic stem cell transplant (HSCT) recipients
‘sterilizing immunity’ 84
HSV 112
steroid therapy
HPV infection 429
infectious mononucleosis 211
see also corticosteroids
Stevens-Johnson syndrome 117
St Louis encephalitis 687-688
control 688
diagnosis 687-688
epidemiology and clinical features 687
St Louis encephalitis virus (SLEV) 673, 687-688
vectors, host range 687
spread and displacement amplification (SDA) 14
Strongyloides stercoralis 885-886
subacute spondylitis 645-656
subacute sclerosing panencephalitis (SSPE) 544-545
clinical course/features 544
diagnosis 552
immunological aspects 550-551
pathogenesis 549-551, 550
risk factors 544
treatment 552
virological aspects 549-550
see also corticosteroids
subacute sclerosing panencephalitis 687-688
subacute spongiform encephalopathies see prion diseases
subconjunctival haemorrhages 613
subtypes/clades
cell tropism 897-898
circulating recombinant forms (CRFs) 897
sudden infant death syndrome (SIDS), influenza 391
supplementary immunization activities (SIAs), polio 618
surgeons
HBV infection 37
HCV infection 37
HIV infection 38
survivin (apoptosis regulator) 259, 825, 840
sustained viral response (SVP) 17-18
swine see pigs (swine)
Subject Index

vaccination
infection reduction by 83
minimum coverage to stop transmission 82, 82
optimal 82
programmes, planning/implementation 89
targeting of specific groups 89
UK programme/service 89
see also vaccination
vaccines
activities for market introduction of 88, 88
administrations routes 86, 87
adverse events 89
antigen dose 86
cost-effect and cost-saving 91, 91
coverage maintenance 89–90
development
historical 85
routes 86
future developments 90
international campaigns and opinions 90
‘killed’ whole-virion 86
live attenuated 86, 89
non-replicative (inactivated) 86
R&D 86–87, 87
regulatory approval 87
replicative 86
safety and efficacy 86–87, 89
social marketing 88, 88
types 86
see also individual virus infections
vaccinia
generalized, after vaccination 634
host, distribution 626
post-vaccinal encephalitis 634
vaccinia immune globulin (VIG) 635
vaccinia virus
modified vaccinia Ankara (MVA) strain 634–635
permeance in environment 49
smallpox vaccination 634
vaccinology 81–93
adverse events 89
burden of disease and reproductive rates 82, 83
disease incidence surveillance 89
future vaccine developments 90
historical aspects 81–82
immune system and artificial immunity 83–85
planning/implementation of programmes 89
principles/practice 82
protective antigen discovery 85–86
protective antigen presentation 86
publicized falsehood rectification 89–90
research and development 86–87, 87
reverse 85
social marketing of vaccines 88, 88
see also vaccination
valaciclovir (Valtrex)
CMV infection 182, 186
prophylaxis 186, 187–188
herpes zoster 152, 154
HSV infections 109, 113, 114, 117
HSV meningitis 124
structure 109
varicella (chickenpox) 151
valganciclovir (VGCV)
CMV infections 181, 189
HSV infections 111
vampire bats, rabies 787, 790, 801
variant Creutzfeldt–Jakob disease (vCJD) 72, 944, 947, 950, 954–956
virology and epidemiology 948–949
age of onset 955
BSE association 954
characteristics/diagnosis 950
clinical onset and features 954–955
epidemic 948
first cases 954
incubation period 949, 955, 957
kuru relationship 956
lymphoreticular infection 955–956
molecular diagnosis 959, 960
neuroinvasion 956
neuropathology 955, 956
pathogenesis 960–961
PRNP 129MM and susceptibility 948, 949, 956
PRNP 129VM 956
prognosis and treatment 961
‘pulvinar sign’ 955
secondary (iatrogenic) 956–957
sporadic CJD vs 956, 957
tonsillar biopsy 955–956, 956, 960–961
transmission 948–949, 960
varicella (chickenpox) 133
children 142, 144
treatment 151–152
clinical features 143–146
complications 144–146
congenital syndrome 145, 145, 152
diagnosis see varicella zoster virus (VZV),
detection/diagnosis
encephalitis 144–145
epidemiology 148, 142–143
haemorrhagic 144
immunocompromised patients 144, 152
incubation period 52, 143
infants 142
neonates 145–146
pathogenesis of infection 139–141, 140
Subject Index

**Y**
- yattapox virus, host, distribution 626
- yellow fever 672, 674–678
  - abortive infection 676
  - age and gender affecting 677
  - clinical features 676–677
  - control 677–678
  - diagnosis 677
  - differential diagnosis 676
  - ‘enzootic forest cycle’ 674
  - epidemiology 674
  - ‘jungle yellow fever cycle’ 674, 676
  - Americas 674, 675
  - Africa 674, 675
  - haemorrhagic diathesis 676
  - history 672
  - incubation period 676
  - mortality 676
  - surveillance for 677
  - transmission cycles 674, 676
  - universal/mass immunization 678
  - ‘urban yellow fever cycle’ 676, 677
  - vaccine 677–678
  - contraindications 678
  - French neurotropic 678
  - pregnancy 678
  - production volume 678
  - side effects 678
  - viraemia 676
- yellow fever virus 672, 674–678
  - Asibi strain 672
  - detection 677
  - distribution and vector 673
  - genotypes 676
  - isolation/cell lines 677
  - pM and E proteins 676
  - transmission 672

**Z**
- zalcitabine
  - HAM treatment 890
- HIV infection 916
- zanamivir
  - HPIV3 infection 413
  - HPIV infection 429
- influenza 60, 398
  - structure 397
- zidovudine
  - adult T-cell leukaemia treatment 890
  - HAM treatment 890
  - HIV infection 916, 923
  - vertical transmission prevention 930
  - prophylactic 930, 931
  - resistance 923, 924, 930
- Zika fever 684
- Zika virus 673, 684
- zinc preparations, rhinovirus infections 500
- Zinga virus 713
- zoonotic infections
  - influenza see influenza A virus; influenza virus
    - retroviruses 869
  - see also individual animals/vectors
- zoster
  - see herpes zoster
  - zoster-associated pain (ZAP) 147
  - treatment 152, 153
- zosteriform herpes simplex (cutaneous HSV) 116
- zoster immunoglobulin (ZIG) 154
- zoster sine herpete 146
- Zovirax see aciclovir